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Abstract: It is known that knockdown of the mitochondrial 18 kDa translocator protein (TSPO) as
well as TSPO ligands modulate various functions, including functions related to cancer. To study the
ability of TSPO to regulate gene expression regarding such functions, we applied microarray analysis
of gene expression to U118MG glioblastoma cells. Within 15 min, the classical TSPO ligand PK 11195
induced changes in expression of immediate early genes and transcription factors. These changes
also included gene products that are part of the canonical pathway serving to modulate general
gene expression. These changes are in accord with real-time, reverse transcriptase (RT) PCR. At the
time points of 15, 30, 45, and 60 min, as well as 3 and 24 h of PK 11195 exposure, the functions
associated with the changes in gene expression in these glioblastoma cells covered well known TSPO
functions. These functions included cell viability, proliferation, differentiation, adhesion, migration,
tumorigenesis, and angiogenesis. This was corroborated microscopically for cell migration, cell
accumulation, adhesion, and neuronal differentiation. Changes in gene expression at 24 h of PK
11195 exposure were related to downregulation of tumorigenesis and upregulation of programmed
cell death. In the vehicle treated as well as PK 11195 exposed cell cultures, our triple labeling showed
intense TSPO labeling in the mitochondria but no TSPO signal in the cell nuclei. Thus, mitochondrial
TSPO appears to be part of the mitochondria-to-nucleus signaling pathway for modulation of
nuclear gene expression. The novel TSPO ligand 2-Cl-MGV-1 appeared to be very specific regarding
modulation of gene expression of immediate early genes and transcription factors.
Keywords: modulation of nuclear gene expression; mitochondrial 18 kDa translocator protein
(TSPO); TSPO ligand; PK 11195; 2-Cl-MGV-1; retrograde mitochondrial-nuclear signaling pathway;
microscopy; mitochondria; cell nucleus
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1. Introduction
Various studies have shown that the 18 kDa translocator protein (TSPO) is involved in numerous
functions, including glioblastoma tumorigenicity in its various aspects, e.g., cell proliferation, cell
viability, etc. [1–5]. A previous common name for TSPO was peripheral-type benzodiazepine receptor
(PBR) [6–8]. TSPO is primarily located in the outer mitochondrial membrane [9–11]. Thus, TSPO
is a mitochondrial protein that interacts with ligands to modulate various molecular biological
mechanisms. In 2006, the name translocator protein, and its acronym (TSPO), was generally
adopted to reflect TSPO’s participation in transport of molecules over the outer mitochondrial
membrane [7,8,12]. Import into mitochondria by the TSPO includes cholesterol, protoporphyrin
IX, and other tetrapyrroles [7,12,13]. Release from the mitochondria regulated by TSPO includes Ca2+,
ATP, and cytochrome c [5,14–16]. TSPO is involved in life essential functions, such as respiration,
photosynthesis, tetrapyrrole metabolism, and programmed cell death [6,8,17,18]. Extensive studies
have shown that TSPO is involved in apoptosis, gene expression, reactive oxygen species (ROS)
generation, ATP production, regulation of the mitochondrial membrane potential (∆Ψm), heme
synthesis, mitochondrial cholesterol transport, neurosteroid synthesis, glutamate metabolism, cell
proliferation, cell adhesion, cell migration, and cell differentiation [3,5,7,12,19,20]. In animals and
humans, TSPO shows essential roles in inflammatory, immune, and stress responses, as well as in
several neuropathological disorders, including neurodegeneration and brain cancer [4,7,12,21]. Based
on this background, we postulated that regulation of nuclear gene expression by the TSPO can go a
long way to explain TSPO’s numerous functional effects [18,22].
It has been shown before that regulation of the TSPO by siRNA or application of TSPO ligands
can affect gene expression in human cells in culture and bacteria [19–26]. The question we address
with this study is whether TSPO is potentially directly involved in mitochondrial capability to regulate
nuclear gene expression. First of all, the question became prominent how TSPO can participate in so
many functions as mentioned above [1–3,13]. We hypothesized that the potential specific capability of
TSPO to regulate gene expression may be the basis of TSPO’s general capability to regulate numerous
functions [13,18,20,22]. The other angle is that it is well known that mitochondria are able to regulate
nuclear gene expression. This phenomenon is called the “retrograde mitochondrial-nuclear pathway
for regulation of nuclear gene expression” [27–31]. It is primarily considered as a cellular response to
stressors, as the second leg of a nuclear-mitochondrial-nuclear loop. For brevity, from here on we will
refer to it as mitochondria-to-nucleus signaling.
Regarding this pathway, mitochondrial ROS generation and loss of ∆ψm have been reported
to take part in mitochondria-to-nucleus signaling [27,32]. This leads to changes in levels of ATP
and NADH and the release of Ca2+, which activates calcium-sensitive proteins, such as calmodulin
and calcineurin. Further downstream this leads to the activation of immediate early genes and
transcription factors [28,29,33,34]. This outline of the mitochondria-to-nucleus pathway mirrors well
reported observations regarding TSPO’s role in mitochondrial functions and mechanisms. It has
been demonstrated that TSPO regulates mitochondrial ROS generation, ∆ψm transitions, and ATP
production [10,11,35,36]. This was originally studied in TSPO’s function of initiating programmed cell
death [3,5,37]. Furthermore, the TSPO ligand PK 11195 induces mitochondrial permeability transition
pore opening, thus allowing release of Ca2+ from the mitochondria into the cytosol [14,38,39]. It has also
been suggested that TSPO can regulate NADPH oxidase (NOX) activity [40–43]. Thus, by regulating
ROS generation, ∆ψm transitions, ATP production, Ca2+ release, and NADH levels, TSPO may be a
key mitochondrial protein providing mitochondria the capability to regulate gene expression in the
cell nucleus.
Therefore, we set out to investigate the effects of the classical TSPO ligand PK 11195 on gene
expression in a time course related fashion. We studied this in cell culture of the U118MG glioblastoma
cell line, as TSPO functions including gene expression have been studied by us for several years in this
cell line (e.g., [5,19,20,24,37,44]). Thereby, we would be able to place the new data in a well-established
context. The assumption was that the earlier the changes in gene expression occur, the more likely it is
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that TSPO takes part in direct control of gene expression, as opposed to secondary effects. Furthermore,
we wanted to see whether genes related to transcription, post transcription, translation, and post
translation would be affected. When changes in gene expression occur before changes in physiological
functions, this would indicate that these changes in gene expression are most likely the causes for the
changes in physiological functions. Specifically, we consider that an early regulation of transcription
factors is indicative of regulation of gene expression. As we are working with glioblastoma cells
(U118MG), one interest also includes how such changes in gene expression regulated by TSPO could
affect tumorigenicity of these cells in this paradigm. For this purpose, we applied the TSPO ligand
PK 11195 (25 µM) for several exposure times (15, 30, and 45 min, and 1, 3, and 24 h). Then, with
the aid of microarray, we assayed changes in gene expression. The choice of 25 µM of PK 11195 is
based on several previous studies that showed no adverse effects with this concentration, while it
counteracts programmed cell death otherwise induced by various agents (e.g., [5,10,13,20,39]). Thus,
in this paradigm PK 11195 at 25 µM only presents beneficial functional effects, including promotion
of cell viability, and no disruptive lethal effects. In this study, apart from targeting the immediate
question of regulation of nuclear gene expression by TSPO ligands, we also address the question
whether modulation of gene expression may be associated with well-known TSPO functions. This was
another reason to focus on PK 11195 at 25 µM, as by application of this concentration we expected to
be better able to connect the present gene expression study with previous functional studies and their
results that applied the same PK 11195 concentration. For these previous studies, dose response assays
for application to U118MG cells were applied, which showed that 25 µM had optimal effects, without
confounding side effects apparent with high doses, while lower doses in the paradigm of programmed
cell death showed no effects by themselves (e.g., [5,10,13,20,44]). We also assayed whether functions
predicted by the changes in gene expression could indeed also be actually observed in the present
study (in particular functions that previously have not been considered part of the TSPO repertoire).
Apart from the classical TSPO ligand PK 11195, we also assayed the effects of the more advanced TSPO
ligand, 2-Cl-MGV-1 [13,20,45], to enhance the generality of the results.
While TSPO location in mitochondria has received a lot of attention, it is also known that TSPO
can be present in perinuclear locations [7,46–48]. To investigate this further, we applied confocal
microscopy to triple labeling of nuclei, mitochondria, and TSPO. Location restricted to the mitochondria
would be supportive of TSPO’s role in mitochondria-to-nucleus signaling for regulation of nuclear gene
expression. Intranuclear location could suggest a nuclear TSPO function, different from a mitochondrial
TSPO function. Other intracellular locations could suggest a more elaborate involvement of TSPO in
regulation of gene expression. As an extra, the study would show whether TSPO function associated
with modulation of nuclear gene expression could correlate with known TSPO functions, and might
possibly also reveal hitherto unknown TSPO functions.
2. Results
The presentation of the Results is divided into 5 parts: (1) PK 11195 effects on gene expression
in general; (2) Potential effects of such gene expression changes on function, uncovered by pathway
analysis; (3) Microscopic correlates at cellular and intracellular levels in association with changes in
gene expression due to PK 11195 exposure; (4) Actual observations of phenotypic effects of PK 11195
exposure that were predicted by pathway analysis; (5) Comparison with effects of a more advanced
TSPO ligand (2-Cl-MGV-1) on gene expression. For pathway analysis, we used the “Regulator Effects”
analytic (IPA®) from Qiagen to gain more insights into the affected functions associated with the
changes in gene expression, as outlined in the Methods.
2.1. PK 11195 Effects on Gene Expression in General
Exposure of U118MG cells to PK 11195 (25 µM) in our paradigm induced changes in gene
expression of 1.5-fold or more of various genes in a time dependent fashion. We took a 1.5-fold change
as a cut off to present changes in gene expression due to application of 25 µM of PK 11195 (Table 1).
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It was also taken into consideration whether groups of genes contributed to changes in functional
pathways as detected by “Regulator Effects” analytic (IPA®). The complete raw data sets are filed with
NCBI, names GSE77998 and “GSE85697” referenced in the section “Referenced Data Sets”. “GSE77998”
indicates gene expression changes after 1, 3, and 24 h of PK 11195 (25 µM) exposure in our paradigm.
“GSE85697” indicates gene expression changes after 15, 30, and 45 min of PK 11195 (25 µM) exposure
in our paradigm.
Table 1. Gene symbols of up-regulated genes and down-regulated genes with their expression changed
due to exposure of U118MG cells to PK 11195 (25 µM) (in comparison to vehicle control in an exposure
time related fashion) (cut off of 1.5): for 15, 30, 45, 60 min, 3, and 24 h.
15–45 min of PK 11195 Exposure (25 µM)
15 min Up-regulated genes ↑ 30 min Up-regulated genes ↑ 45 min Up-regulated genes ↑
FOS ↑ +2.16 FOS ↑ +3.96 EGR1 ↑ +2.45
DUSP1 ↑ +2.08 DUSP1 ↑ +3.64 PTGS2 ↑ +2.00
EGR1 ↑ +1.89 EGR1 ↑ +2.64 FOS ↑ +1.84
CYR61 ↑ +1.82 CYR61 ↑ +2.16 DUSP1 ↑ +1.77
OSR1 ↑ +1.71 MYC ↑ +2.03 FOSB ↑ +1.72
ANP32AP1 ↑ +1.64 CXCL8 ↑ +2.02 CYR61 ↑ +1.69
FKBP10 ↑ +1.54 PTGS2 ↑ +2.01 SGK1 ↑ +1.67
RNA28S5 ↑ +1.54 CTGF ↑ +1.93 CXCL8 ↑ +1.62
DYNC1H1 ↑ +1.52 NFKBIZ ↑ +1.90 ATF3 ↑ +1.58
WNK1 ↑ +1.51 SGK1 ↑ +1.89 ANP32AP1 ↑ +1.58
15 min Down-regulated genes ↓ 30 min Down-regulated genes ↓ 45 min Down-regulated genes ↓
ID3 ↓ −1.83 LOC100507412 ↓ −1.72 MYLIP ↓ −1.84
TUFT1 ↓ −1.83 TUFT1 ↓ −1.51 LOC441087 ↓ −1.50
ID2 ↓ −1.68 MYLIP ↓ −1.50
PTMA ↓ −1.60 KDM3A ↓ −1.50
ID1 ↓ −1.56
KDM3A ↓ −1.55
NABP1 ↓ −1.52
RPL21P28 ↓ −1.50
CLK1 ↓ −1.50
1–24 h of PK 11195 Exposure (25 µM)
1 h Up-regulated genes ↑ 3 h Up-regulated genes ↑ 24 h Up-regulated genes ↑
CYR61 ↑ +9.3 ID3 ↑ +3.38 ASN ↑ +2.47
FOSB ↑ +4.29 ID1 ↑ +2.08 SLC7A5 ↑ +2.39
EGR2 ↑ +3.32 GBP1 ↑ +2.04 TRIB3 ↑ +2.21
EGR1 ↑ +3.2 SMAD6 ↑ +1.89 PCK2 ↑ +2.18
CTGF ↑ +3.04 ID2 ↑ +1.86 LOC729779 ↑ +2.12
ID3 ↑ +2.62 ATOH8 ↑ +1.85 PSAT1 ↑ +1.97
TUFT1 ↑ +2.49 TXNIP ↑ +1.84 NUPR1 ↑ +1.94
ID1 ↑ +2.33 NEXN ↑ +1.77 P8 ↑ +1.88
SRF ↑ +2.15 SLC3A2 ↑ +1.74 DDIT4 ↑ +1.84
GBP1 ↑ +2.12 ACTG2 ↑ +1.71 FAM102A ↑ +1.82
PTGS2 ↑ +2.11 FHL2 ↑ +1.65 SLC1A5 ↑ +1.8
TRIB1 ↑ +2.09 DDIT3 ↑ +1.8
ERRFI1 ↑ +2.04 ATF4 ↑ +1.77
ATF3 ↑ +1.95 TGIF1 ↑ +1.75
KLF6 ↑ +1.74 SPRR2D ↑ +1.72
FOS ↑ +1.73 PHGDH ↑ +1.71
DUSP5 ↑ +1.71 SLC3A2 ↑ +1.69
PTGER4 ↑ +1.69 PLEKHF1 ↑ +1.67
SGK ↑ +1.69 FOLR3 ↑ +1.65
GADD45A ↑ +1.69 BEX2 ↑ +1.63
SGK1 ↑ +1.69 SLC6A15 ↑ +1.63
ID2 ↑ +1.68 IGFBP1 ↑ +1.56
FILIP1L ↑ +1.67
1 h Down-regulated genes ↓ 3 h Down-regulated genes ↓ 24 h Down-regulated genes ↓
BCL6 ↓ −2.14 IL8 ↓ −2.47 MYLIP ↓ −2.24
DDIT4 ↓ −1.72 MYLIP ↓ −2.36 UHRF1 ↓ −1.80
SOX4 ↓ −1.89 IGFBP5 ↓ −1.79
RGS4 ↓ −1.72
PDE5A ↓ −1.69
TYMS ↓ −1.65
ERRFI1 ↓ −1.63
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As mentioned in the Introduction, we applied 25 µM of PK 11195 as this was an effective
concentration determined in previous studies, in particular regarding regulation of programmed
cell death, including modulation of mitochondrial membrane potential (∆Ψm), reactive oxygen
species (ROS) generation, and cytochrome c release from mitochondria of U118MG cells. Importantly,
this concentration also precludes confounding side effects [5]. Thereby, we assumed we would be
able to associate our results with a previously established context [2,13]. First of all, we attained a
general overview of gene expression changes following application of 25 µM of PK 11195, including
magnitude and direction of changes in gene expression (Table 1). This provided a detailed time-course
of changes in gene expression (Table 1).
After having determined changes in gene expression due to PK 11195 exposure in a time
dependent fashion, we moved on to assay effects on function in general, in particular regarding
induction of changes in gene expression and potentially subsequent functional effects (Table 2).
Table 2 presents the gene symbols of the genes with significantly changed expression due to PK
11195 treatment, together with the general nature of the gene products (transcription factors, proteins,
enzymes, and other products). Thus, as Table 1 provides a detailed time-course of changes in gene
expression, Table 2 provides a detailed time course of related functional effects typically associated
with the genes in question.
In short, starting at the left hand column of Table 2:
• Within 15 min, 20 genes significantly changed their expression rate in comparison to vehicle
control, and 11 of them code for transcription factors, the other 9 code for proteins, enzymes, and
other products.
• After 30 min (indicated in the second column) 14 genes changed significantly their expression
rate from vehicle control. At this time point the number of genes coding for transcription factors
is 6, the other 8 genes code for proteins, enzymes, and other products.
• After 45 min of PK 11195 exposure (indicated in the third column), 12 genes have their expression
changed significantly from vehicle control, 5 of them coding for transcription factors, the other
7 genes code for proteins, enzymes, and other products.
• After 1 h (indicated in the fourth column), 25 genes significantly changed their expression rate,
and 14 of them code for transcription factors, the other 11 code for proteins, enzymes, and
other products.
• After 3 h (indicated in the fifth column), 14 genes changed significantly their expression rate
from vehicle control. The number of genes coding for transcription factors at this time point is 6,
the other 8 genes code for proteins, enzymes, and other products.
• After 24 h of PK 11195 exposure (indicated in the sixth column), 29 genes have their expression
changed significantly from vehicle control. The number of genes coding for transcription factors
is 6 after 24 h of PK 11195 exposure, the remaining majority of the genes (23 genes) codes for
proteins, enzymes, and other products at this time point. Indeed, the biggest numbers of gene
expression changes for proteins, enzymes, and other products is after 24 h.
As TSPO is well known to regulate programmed cell death, in Table 2 is also indicated with
asterisks (*) which genes can be associated with programmed cell death. At every time point within
the first hour of PK 11195 exposure, more than half of the genes with significantly changed gene
expression are associated with programmed cell death. This number is smaller at 3 h and 24 h of PK
11195 exposure.
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Table 2. Gene symbols of the genes with changed expression after15, 30, 45, 60 min, 3, and 24 h of PK
11195 exposure (of 25 µM), arranged according to their overall functions as analyzed with “Regulator
Effects” analytic (IPA®). These overall functions are listed as: transcription factors, proteins, enzymes,
and other products. Asterisks (*) indicate genes associated with programmed cell death. Other products
include pseudogenes, ribosomal factors, etc. Further, the function of not all gene products is fully
known. This time course presents 2 peaks for enhanced expression of transcription factors (at 15 min
and at 1 h). Gene products including proteins, enzymes, and other products peak at 24 h.
Gene Expression Changes in U118MG Glioblastoma Cells after PK 11195 Exposure for different Time Periods
15 min 30 min 45 min 60 min 3 h 24 h
All Types of Genes Combined
20 Genes 14 Genes 12 Genes 25 Genes 14 Genes 29 Genes
Transcription Factors
ATF3 *
BCL6 *
DUSP5
CLK1 EGR1 *
DUSP1 * EGR2 *
EGR1 * FOS *
FOS * FOSB *
OSR1 * GADD45A *
ID1 * DUSP1 * ID1 * ATOH8 ATF4 *
ID2 * EGR1 * ATF3 * ID2 * ID1 * DDIT3 *
ID3 * FOS * DUSP1 * ID3 * ID2 * NUPR1 *
KDM3A * KDM3A EGR1 * KLF6 * ID3 * TGIF1
NABP1 MYC * FOS * SRF SOX4 TRIB3 *
PTMA * NFKBIZ * FOSB * TRIB1 * SMAD6 * UHRF1
(11 genes) (6 genes) (5 genes) (14 genes) (6 genes) (6 genes)
Proteins, Enzymes, and other Products
ASNS *
BEX2 *
DDIT4 *
ERRFI1
FAM102A
FOLR3
IGFBP1 *
IGFBP5 *
LOC729779
MYLIP
PCK2
PDE5A
CTGF * PHGDH
CYR61 * PLEKHF1
ANP32AP1 DDIT4 * P8
CYR61 * CTGF * ERRFI1 ACTG PSAT1
DYNC1H1 * CXCL8 ANP32AP1 GBP1 FHL2 * RGS4
FKBP10 CYR61 * CXCL8 FILIP1L GBP1 SLC1A5
MIR22HG LOC100507412 CYR61 * PTGER4 IL8 SLC3A2
RNA28S5 MYLIP LOC441087 PTGS2 * MYLIP SLC6A15
RPL21P28 PTGS2 * MYLIP SGK NEXN SLC7A5
TUFT1 SGK1 * PTGS2 * SGK1 * SLC3A2 SPRR2D
WNK1 TUFT1 SGK1 * TUFT1 TXNIP * TYMS
(9 genes) (8 genes) (7 genes) (11 genes) (8 genes) (23 genes)
2.2. Implied Specific Functional Effects due to Gene Expression Changes Induced by Various PK 11195
Exposure Times
We used the “Regulator Effects” analytic (IPA®) to gain more insights into the potentially affected
functions associated with the changes in gene expression. This showed that the products of at least
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some of the genes having their expression modulated after 15 min of exposure to PK 11195 are part of
the canonical pathway for regulation of gene expression (Figure 1). These genes include WNK1, FOS,
SGK, and MYC. Thus it appears that regulation or enabling of changes in nuclear gene expression in
general indeed is one of TSPO’s functions.
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analytic (IPA®). The gene products of the genes WNK1, FOS, SGK, and MYC that are activated by the 
translocator protein (TSPO) ligand PK 11195 all are part of canonical pathways that converge on the 
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MYC) that are highlighted in the canonical pathway for induction of gene expression changes 
presented in Figure 1, together with the 3 genes in Table 1 that showed most pronounced changes in 
gene expression (FOS, DUSP1, EGR1). FOS, DUSP1, and EGR1 also are among the immediate early 
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Figure 1. Specific elements of the canonical pathway for modulation of gene expression that are
activated after 15 min of exposure of U118MG cells to 25 µM of PK 11195, as uncovered by “Regulator
Effects” analytic (IPA®). The gene products of the genes WNK1, FOS, SGK, and MYC that are activated
by the translocator protein (TSPO) ligand PK 11195 all are part of canonical pathways that converge on
the final function of gene expression regulation. Furthermore, the statistically significant enhancements
of expressions of the genes WNK1, FOS, SGK, and MYC all peak within one hour of exposure to PK
11195 (see Figure 2).
In Figure 2A, we established the time response curves of these 4 genes (WNK1, FOS, SGK,
and MYC) that are highlighted in the canonical pathway for induction of gene expression changes
presented in Figure 1, together with the 3 genes in Table 1 that showed most pronounced changes in
gene expression (FOS, DUSP1, EGR1). FOS, DUSP1, and EGR1 also are among the immediate early
genes and transcription factors presented in Table 2. Note: the immediate early gene FOS is also
part of the canonical pathway for induction of gene expression changes. Interestingly, the immediate
early genes FOS, DUSP1, and EGR1 consistently showed enhanced gene expression after 15, 30, and
45 min of exposure to PK 11195 (Figure 2A). Enhanced expression of WNK1, one of the initiators of the
canonical pathway for gene expression, already peaks at 15 min. FOS, MYC, and SGK that are part of
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the intranuclear end of the canonical pathway for gene expression peak their expression at 30 min.
DUSP1 also peaks at 30 min. EGR1 has a “small” peak at 30 min and a “high” peak at 60 min. Real time,
reverse transciptase (RT)-PCR data showed increases in expression of FOS and DUSP1 compared to
control by 7.5 and 3.5-fold, respectively, corroborating the microarray data. In some detail, Table 3 gives
the numbers of the Ct’s of FOS and DUSP1, showing that RT-PCR also gives significant differences for
the expression of these genes at 30 min of exposure as microarray also showed. Figure 2B gives the
fold changes provided by the 2−∆∆Ct analysis of the FOS and DUSP1 expression at 30 min measured
with RT-PCR. Note regarding Figure 2B, since the samples vehicle and treated groups are not paired
we are under obligation to use their averages for calculation of 2−∆∆Ct which thus gives only one data
point for each gene presented by the columns in Figure 2C, and consequently no error bars. It is for this
reason that we also provide Table 3, which does give the SD’s of the Ct’s of FOS and DUSP1 expression.
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Figure 2. Effects of PK 11195 exposure on several immediate early genes of U118MG cells. (A) Time
course of gene expression for gene products well known to take part in the initiation of modulation of
gene expression assayed with microarray. These genes (WNK1, FOS, DUSP1, EGR1, MYC, SGK1) all
present a peak of increased expression within half an hour of exposure of U118MG cells to 25 µM of
PK 11195. As the data for 15, 30, and 45 min are obtained from one microarray and for 1, 3, and 24 h
obtained from another microarray, a bar is placed between 45 and 60 min as a separation between the
two. (Each micro array had its own untreated control as detailed in the Methods’ section); (B) Fold
change (2−∆∆Ct) of FOS and DUSP1 expression after exposure to PK 11195 is 7.5 and 3.5, respectively,
co pared to untreated control (vehicle).
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Table 3. Real-time RT-PCR analysis (Ct) of FOS, DUSP1, and B2M expression in glioblastoma cells
after 30 min exposure to 25 µM of PK 11195. The presentation of the Ct data as means ± SD.
*** p < 0.001, ** p < 0.01, n = 2 (One way ANOVA, posthoc Bonferroni, multiple comparisons) shows
the statistical significances of the differences between vehicle (i.e., untreated control) and PK 11195
(i.e., the treated groups) for FOS and DUSP. Each member of the biological duplicates is the average
of 2 technical duplicates. Biological duplicates means cells grown in 2 different wells i.e., truly
independent measurements. Technical duplicates means two measurements on the same biological
sample (to achieve better accuracy); their average in the end thus is just one measurement.
Ct Vehicle PK 11195
B2M 22.10 ± 0.85 21.85 ± 0.21 n.s.
FOS 29.35 ± 0.07 26.20 ± 0.28 ***
DUSP1 24.90 ± 0.42 22.85 ± 0.21 **
The postulated functional effects due to the gene expression changes seen at the different time
points as provided by “Regulator Effects” analytic (IPA®) are given in Table 4. As the detailed
presentations of the outcomes of these analyses are very elaborate for each of the time points, they are
provided in the supplementary materials. In the body of the results, we have given examples of the
results of this analysis for 15 min in Figures 1–3, and for 24 h in Figures 4 and 5, as at these time points
the outcome of the analysis is relatively straightforward, and insightful. For completeness, the results
of the analysis for all the time points 15, 30, 45, and 60 min, and of 3 and 24 h are provided in the
supplementary files, and presented summarily here in the Results section, e.g., in Table 4.
The functional effects displayed in Table 4 are provided by the downstream components
(“Effects”), given by the application of “Regulator Effects” analytic (in IPA®) to our data. This gives
insights into potential phenotypic and physiological effects that may result from the changes in gene
expression due to exposure of U118MG cells to 25 µM of PK 11195, including the time-course of the
phenotypic and physiological changes. The gene expression data for each time point, provided by the
microarray assays, is given in the “Data Sets” of the figures that present the “Regulator Effect”. In the
body of the text, these figures are given only for 15 min and 24 h of PK 11195 exposure (Figures 3–5).
The “Regulators” and “Effects” present what is known regarding upstream regulation and downstream
effects of these genes. For the complete overview of the time points of 15, 30, 45 min, 1, 3, and 24 h,
providing for the time course of these events, see the appendices. These appendices present “Data
Sets”, “Regulators”, and “Effects” for each time point.
As examples in the body of the Results, the “Effects” are presented in the bottom tiers of
Figures 3–5 for PK 11195 exposures of 15 min and 24 h. The “Effects” present the functional, phenotypic,
and disease related effects that are known to be under control of the genes with changed expression in
our study. The middle tiers of these Figures 3–5 present the genes with changed expression determined
in our study (the “Data Sets”) as exemplified by “Regulator Effects” analytic (IPA®). The “Regulators”
presented in the top tiers of these diagrams of Figures 3–5 are factors (genes, RNAs, proteins) that
reportedly can modulate expression of the genes of our “Data Sets”. As mentioned, the appendices
also show the assayed time points between 15 min and 24 h.
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Table 4. Functional effects implied by the gene expression modulated by PK 11195. This was acquired by application of “Regulator Effects” analytic (IPA®). The time
points of 15, 30, 45 min, 1, 3, and 24 h applied in this study are given, providing a time-course of functional changes. (The modulated gene expression itself is presented
in Tables 1 and 2.) In the appendices more detailed presentations of the outcomes of “Regulator Effects” analytic (IPA®) are given for each time point. Functions that
are upregulated are given here in bold red, functions that are down regulated are given in blue.
15 min 30 min 45 min 1 h 3 h 24 h
Gene
expression modulation
Binding of protein
binding site
Transactivation of RNA
Endothelial cell
development
Cell viability
Accumulation of cells
Binding of protein
binding site
Synthesis of DNA
Differentiation of
connective tissue cells
Development of neurons
Formation of cells
Microtubule dynamics
Chemotaxis of cells
Cell movement of
fibroblast cell lines
Metastasis of tumor
cell lines
Abdominal neoplasm
Proliferation of
lymphocytes
Growth of tumor
Cell viability
Metabolism of
carbohydrate
Inflammation of
body region
Synthesis of DNA
Development of neurons
Formation of cellular
protrusions
Angiogenesis
Proliferation
Migration
Cell growth
Apoptosis of fibroblast
cell lines
Malignant solid tumor
S phase
Cell cycle progression of
fibroblast cell lines
Development of
cardiovascular system
Cell viability
Formation of cellular
protrusions
Growth of
malignant tumor
Proliferation of
tumor cells
Formation of cells
Development of
reproductive system
Cell death of central nervous
system cells
Apoptosis of fibroblasts
Apoptosis of myeloid cells
Apoptosis of muscle cell lines
Necrosis of epithelial tissue
Migration of colon cancer
cell lines
Cell movement of leukocyte
cell lines
Migration of smooth
muscle cells
Migration of phagocytes
Chemotaxis
Cell viability
Development of
epithelial tissue
Proliferation of leukocyte
cell lines
Activation of leukocytes
Inflammatory response
Accumulation of leukocytes
Proliferation of leukemia
cell lines
Activation of tumor cell lines
Cell death of fibroblast
cell lines
Apoptosis of kidney
cell lines
Apoptosis of epithelial
cell lines
Abdominal cancer
Digestive system cancer
Growth of digestive
organ tumor
Growth of
malignant tumor
Epithelial cancer
Proliferation of
tumor cells
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Figure 3. It presents the effects associated with changes in gene expression of 15 min of PK 11195 
exposure, as determined with “Regulator Effects” analytic (in IPA®) from Qiagen as indicated in the 
figure (see also the Methods). The middle tier presents the genes showing significantly changed 
expression (“Data Set” in the middle tier). The “Effects” presented in the bottom tier indicate that, 
due to the significant changes in gene expression presented in the “Data Set”, the following general 
functions can be upregulated: (1) Binding of protein binding site; (2) Transactivation of RNA; (3) 
Endothelial cell development; (4) Accumulation of cells; and (5) Cell viability. The top tier presents 
the ‘Regulators’ known to be associated with these “Effects” and the genes of the “Data Set”. The 
arrows indicate the directions of the pathways, from Regulators, to Data Set, to Effect. 
Figures 3–5 show that in these paradigms individual “Regulators” can modulate genes’ 
expression from clusters of various sets of genes. A set of genes that can be modulated by one 
“Regulator” that affects one particular “Effect” can be considered an assembly. Such assemblies can 
be seen in Figures 4 and 5 (describing gene expression effects for 24 h of PK 11195 application). 
Interacting and overlapping assemblies can be considered super-assemblies. One such super-
assembly is presented in Figure 3 (describing gene expression effects for 15 min of PK 11195 
application, which actually is a relatively simple super-assembly). In the appendices, the super-
assemblies induced by 15, 30, 45, and 60 min, and 3 and 24 h of PK 11195 exposures are given with 
more additional details. The assemblies and super-assemblies indicate to us that the functions 
affected are not based on the changes in expression of just one single gene, but based on several genes. 
This indicates that the postulations of changes in functions are robust. General terms used for these 
phenomena providing robustness regarding regulation are “redundancy” and “degeneracy” as 
exemplified in the Discussion [49–51]. We favored the application of ‘Regulator Effects’ analytic 
(IPA®), and the unadulterated presentation of its outcomes, to avoid selective bias potentially 
introduced by preconceived interpretations of what the effects should be. This way of gene 
expression analysis is particularly useful for TSPO research as it is well known that TSPO affects a 
broad variety of functions [1,2,13]. The functional effects are presented below, in a temporal fashion: 
 Regarding functional effects at 15 min, in addition to upregulation of gene expression, in general, 
several functions appeared to be affected. In particular, binding of protein binding site, 
transactivation of RNA, cell development, cell viability, and accumulation of cells (Table 4, 
Figure 3). As seen in Figure 3, 15 min of PK 11195 activates a super-assembly including 5 
Regulators, 8 genes, and 5 Effects. In Figures 1 and 2 is shown that PK 11195 application for 15 
min affects the canonical pathway for regulation of gene expression. 
Figure 3. It presents the effects associated with changes in gene expression of 15 min of PK 11195
exposure, as determined with “Regulator Effects” analytic (in IPA®) from Qiagen as indicated in
the figure (see also the Methods). The middle tier presents the genes showing significantly changed
expression (“Data Set” in the middle tier). The “Effects” presented in the bottom tier indicate that, due to
the significant changes in gene expression presented in the “Data Set”, the following general functions
can be upregulat d: (1) Binding of protein binding sit ; (2) Transactivation of RNA; (3) Endoth lial cell
developm nt; (4) Accumulation of cells; and (5) Cell viability. The top ti r pres nts the ‘Regulators’
known to be associat d with these “Effects” and the genes of the “ ta Set”. Th arrows indicate the
directions of the pathways, from Regulators, to Data Set, to Effect.
Figures 3–5 show that in these paradigms individual “Regulators” can modulate genes’ expression
from clusters of various sets of genes. A set of genes that can be modulated by one “Regulator”
that affects one particular “Effect” can be co sidered an assembly. Such assemblies can be seen in
Figure 4 and 5 (describing gene expression effects for 24 h of PK 11195 applicatio ). Interacting and
overlapp ng assemblies an be considered super-assemblies. One such super-assembly is presented in
Figure 3 (describing gene expression effects for 15 min of PK 11195 application, which actually is a
relatively simple super-assembly). In the appendices, the super-assemblies induced by 15, 30, 45, and
60 min, and 3 and 24 h of PK 11195 exposures are given with more additional details. The assemblies
and super-assemblies indicate to us that the functions affected are not based on the changes in
expression of just one single gene, but based on several genes. This indicates that the postulations
of changes in functions are robust. General terms used for these phenomena providing robustness
regarding regulation are “redundancy” and “degeneracy” as exemplified in the Discussion [49–51].
We favored the application of ‘Regulator Effects’ analytic (IPA®), and the unadulterated presentation
of its outcomes, to avoid selective bias pote tially introduced by preconceived in rpret tions f what
the effects should be. This way of gene expression analysis is particularly useful for TSPO research
as it is well known that TSPO affects a broad variety of functions [1,2,13]. The functional effects are
presented below, in a temporal fashion:
• Regarding functional effects at 15 min, in addition to upregulation of gene expression, in
general, several functions appeared to be affected. In particular, binding of protein binding
site, transactivation of RNA, cell development, cell viability, and accumulation of cells (Table 4,
Figure 3). As seen in Figure 3, 15 min of PK 11195 activates a super-assembly including 5
Regulators, 8 genes, and 5 Effects. In Figures 1 and 2 is shown that PK 11195 application for
15 min affects the canonical pathway for regulation of gene expression.
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• Functional effects at 30 min appeared to be more varied than at 15 min of PK 11195 exposure.
For simplification, these effects can be classified as: binding of protein binding site, cell division
and proliferation, cell viability, metabolism, cell differentiation, cell motility, tumorigenicity, and
tissue inflammation. These functions are listed in more detail in Table 4. The super-assembly that
can be distinguished at 30 min is elaborate and includes 26 Regulators, 19 genes, and 15 Effects.
This super-assembly is provided in the supplementary files.
• After 45 min, cell differentiation effects appeared to be the core functional aspect of the gene
expression changes, as well as angiogenesis, proliferation, migration, and cell growth (Table 4).
The super-assembly seen at 45 min is relatively small, 9 Regulators, 9 genes, and 3 Effects
(provided in the supplementary files). Both the 30 and 45 min of PK 11195 exposures caused gene
expression changes associated with the canonical pathway for angiogenesis, also provided in the
supplementary files.
• After 1 h, the functional effects in general appeared to include: upregulation of cell cycle,
proliferation, cell differentiation, cell viability, and tumorigenesis, but also programmed cell
death. These functions are listed in more detail in Table 4. The super-assembly seen at 1 h includes
19 Regulators, 29 genes, and 12 Effects (provided in the supplementary files).
• After 3 h, the general effect due to changes in expression of the various genes after exposure of
U118MG cells to 25 µM of PK 11195 appears to imply a less tumorigenic phenotype. The majority
of the ‘Effects’ of 3 h of PK 11195 exposure can be classified as down regulation. This down
regulation relates to (1) Migration; (2) Inflammatory response; (3) Proliferation, (4) Development,
including cell differentiation; (5) Cell viability; and (6) Tumorigenesis. These ‘Effects’ after 3 h are
virtually the opposite from those seen after the shorter PK 11195 exposures. These functions are
listed in more detail in Table 3. In contrast, programmed cell death is still upregulated, as was
also seen after 1 h of PK 11195 exposure. These functions are listed in more detail in Table 4.
The super-assembly activated by 3 h of PK 11195 exposure includes 23 Regulators, 30 genes,
and 18 Effects, presented in the supplementary files.
• After 24 h of PK 11195 exposure, pathway analysis with the “Regulator Effects” analytic (IPA®)
indicated that due to the significant changes in gene expression only the following general function
is down-regulated: tumorigenicity (Figure 4). Several separate pathways were revealed regarding
tumorigenicity, each one including just one “Regulator” and a small set of genes forming the
“Data Set” (Figure 4A–C). Additional figures in the Supplementary Materials give additional,
somewhat more complicated information, i.e., 2 or 3 “Regulators” together modulating ‘Data Sets’
of a dozen to several dozen genes (Supplementary Materials). These figures also impinge on the
general theme of reduced tumorigenicity. Thus, after 24 h of PK 11195 exposure no extensive
super-assembly was recognized, but several independent assemblies downregulating several
aspects of tumorigenicity and upregulation of programmed cell death (Figures 4 and 5).
Regarding programmed cell death , with all PK 11195 exposure times, “Regulator Effects” analytic
(IPA®) of Qiagen indicated significant changes in gene expression associated with programmed cell
death (Table 2).
Taking the whole time sequence of responses to PK 11195 into account, it appears that during
the first hour upregulation of tumorigenic responses prevails. At 60 min pro-aptotic gene products
become relevant and remain so till at least 24 h after PK 11195 exposure. Furthermore, at 3 and 24 h of
PK 11195 exposure, down regulation of tumorigenic responses becomes predominant. This response
sequence may be interpreted as homeostatic.
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Figure 4. Potential effects on tumorigenicity due to gene expression following 24 h of exposure of 
U118MG cells to PK 11195 (25 µM). As determined with “Regulator Effects” analytic (IPA®) from 
Qiagen as indicated in the figure (see also the Methods)., in (A–C), individual “Regulators” (given in 
the upper tiers) are related to specific groups of genes with significantly changed expression (“Data 
Sets” given in the middle tiers), together with their particular downstream functions (“Effects” in the 
bottom tiers), namely, suppression of growth of malignant tumor (in (A) and suppression of 
proliferation of tumor cell lines (in (B,C). Color coding: pink/orange = upregulated, blue/green = down 
Figure 4. Potential effects on tumorigenicity due to gene expression following 24 h of exposure of
U118MG cells to PK 11195 (25 µM). As determined with “Regulator Effects” analytic (IPA®) from
Qiagen as indicated in the figure (see also the Methods)., in (A–C), individual “Regulators” (given in the
upper tiers) are related to specific groups of genes with significantly changed expression (“Data Sets”
given in the middle tiers), together with their particular downstream functions (“Effects” in the bottom
tiers), namely, suppression of growth of malignant tumor (in (A) and suppression of proliferation of
tumor cell lines (in (B,C). Color coding: pink/orange = upregulated, blue/green = down regulated.
The configurations in seen in (A–C) can be considered assemblies. The arrows indicate the directions
of the pathways, from Regulators, to Data Set, to Effect.
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Figure 5. Potential effects on programmed cell death due to gene expression following 24 h of 
exposure of U118MG cells to PK 11195 (25 µM). As analyzed with Regulator Effects analytic (IPA®) 
from Qiagen as indicated in the figure (see also the Methods), in A,B,C, individual “Regulators” 
(given in the upper tiers) are related to specific groups of genes with significantly changed expression 
(“Data Sets” given in the middle tiers), together with their particular downstream functions (“Effects” 
in the bottom tiers), namely, stimulation of apoptosis of kidney cell lines (in (A), stimulation of 
apoptosis of epithelial cell lines (in (B)), stimulation of cell death of fibroblast cell lines (in (C). Each 
mentioned separate set can be considered an assembly of pathways running from 1 or few Regulators 
via a number of genes to affect not more than 1 or 2 specific functions. Color coding: pink/orange = 
upregulated, blue/green = down regulated. The configurations in seen in (A–C) can be considered 
assemblies. The arrows indicate the directions of the pathways, from Regulators, to Data Set, to Effect. 
2.3. Microscopic Correlates at Cellular and Intracellular Levels in Association with Changes in Gene 
Expression due to PK 11195 Exposure 
To see whether the changes in gene expression due to PK 11195 exposures, seen at the different 
time points in the present study, may be associated with changes in TSPO location, confocal 
microscopy was applied (Figure 6). A priori, we had expected to see TSPO expression appearing in 
the cell nucleus after PK 11195 exposure, in association with the apparent modulation of gene 
expression. Actually, we did not expect to see changes in gene expression before 24 h. Thus, we 
expected changes in gene expression to come only after 24 h of PK 11195 exposure, potentially even 
associated with a shift in TSPO location. However, as mentioned above, changes in gene expression 
determined with microarray were already apparent within 15 min of PK 11195 application. As the 
gene expression assay, also our microscopic study started with the time point of 15 min, and included 
30, and 45 min, 1, 3, and 24 h. A general overview of the results is given in Figure 6. For simplification, 
Figure 6 is restricted to the time points of 0 min exposure (vehicle control), 30, 45 min, 1, and 24 h. 
We found that in all instances, i.e., in vehicle control as well as at all of the time points for PK 11195 
exposed cells, immunocytological TSPO labeling appears to be restricted to the cytosolic 
compartment of the cell, including the mitochondria (labeled with Mitotracker red). To emphasize, 
TSPO labeling does not double-label with DAPI labeling of the cell nuclei, as can be seen clearly in 
the columns named “Nucleus, TSPO” of Figures 6 and 7. 
Figure 5. Potential effects on programmed cell death due to gene expression following 24 h of exposure
of U118MG cells to PK 11195 (25 µM). As analyzed with Regulator Effects analytic (IPA®) from Qiagen
as indicated in the figure (see also the Methods), in A,B,C, individual “Regulators” (given in the upper
tiers) are related to specific groups of genes with significantly changed expression (“Data Sets” given
in the middle tiers), together with their particular downstream functions (“Effects” in the bottom tiers),
namely, stimulation of apoptosis of kidney cell lines (in (A), stimulation of apoptosis of epithelial cell
lines (in (B)), stimulation of cell death of fibroblast cell lines (in (C). Each mentioned separate set can be
considere an assembly of pathways running fro 1 or few Regulators via a nu ber of genes to affect
not more than 1 or 2 specific functions. Color coding: pink/orange = upregulated, blue/green = down
regulated. The configurations in seen in (A–C) can be considered assemblies. The arrows indicate the
dir ctions of the pathways, from Regulators, t Data Set, to Effect.
2.3. Microscopic Correlates at Cellular and Intracellular Levels in Association with Changes in Gene Expression
due to PK 11195 Exposure
,
points in the present study, may be associated with changes in TSPO location, confocal mi roscopy
was applied (Figure 6). A priori, we had expected to se TSPO expression app aring in the cell nucleus
after PK 11195 exposure, in association with the apparent modulation of g e expression. Actually,
we did not expect to see cha ges in gene expression before 24 h. Thus, we exp cted changes in
gen expression to com only after 24 h of PK 11195 exposure, potentially even ass cia ed with a
shift in TSPO location. However, as menti ned above, changes in gen expression determined with
microarray ere already apparent within 15 min of PK 1119 application. As the gene expre sion
assay, also our microscopic study started with the time poin of 15 min, and included 30, and 45 min,
1, 3, and 24 h. A general overview of the results is given in Figure 6. For simplification, Figure 6 is
restricted to the time points of 0 mi exposure (vehicle control), 30, 45 min, 1, and 24 h. We found
that in all insta ces, i.e., i vehicle control as well as at all of the time points for PK 11195 exposed
cells, immunocytological TSPO labeling appe rs to be restricted to th cytosolic compartment f the
ell, including the mitochondria (labeled wit Mitotrack r red). To emph size, TSPO labeling do s
not dou le-label with DAPI labeling of t e cell nucl i, as can be see clearly in the columns named
“Nucle s, TSPO” of Fig res 6 and 7.
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Figure 6. Phase contrast microscopic images of U118MG cells labeled for the cell nucleus (DAPI), the 
mitochondria (Mitotracker Red), and TSPO (immunocytological labeling). The images are indicative of 
morphological changes due to exposure to the TSPO ligand PK 11195, in association with intracellular 
TSPO location. In general, as described in the text, the main points are that TSPO does not appear in the 
cell nuclei, but are always co-localized with mitochondria. The arrow-heads indicate labeling of 
mitochondria and TSPO evenly distributed throughout the cytoplasm in the vehicle row. In the 45 min 
row, the arrows point at mitochondria with co-localized TSPO that are present relatively close to the cell 
nuclei. A more detailed description of the figure follows here: The rows present exposure times to PK 
11195 (25 µM), from top to bottom: vehicle (i.e., no exposure), 30, 45 min, 1, and 24 h. In each row from 
column to column the same cells are shown. Phase contrast micrographs are presented in the first 
column. The second column shows cell nuclei (stained blue with the aid of DAPI) within the phase 
contrast images. The third column shows TSPO immune labeling (Alexa fluorR 488, i.e., green) 
together with the DAPI stained nuclei. Most importantly, the images in the third column show that 
TSPO labeling is not within the cell nuclei, but in other intracellular areas and cell organelles. In 
particular, there is no double-labeling of TSPO and DAPI signal. The fourth column shows 
mitochondrial labeling in the cells outlined by phase contrast. Here it becomes clear that the TSPO 
labeling in the third column covers intracellular areas occupied by mitochondria. The fifth column 
shows the results of all signals for the cells in question combined. This presents merged double labeling 
for mitochondria and TSPO (white to yellow), while phase contrast and nuclear stain is applied for 
orientation. The DAPI stained nuclei appear purple here due to interference. As a control for this, 
omission of TSPO labeling i.e., by omitting the primary anti-TSPO anti-body, results in the same 
nuclear stain (purple) when applying the same microscopic conditions (not shown). As a general 
remark, omission of TSPO antibody completely prevented the immunocytochemical labeling for 
TSPO (not shown). The scale bar of 20 µm in the lower left corner of the figure is for all the 
micrographs in this plate. 
Figure 6. Phase contrast microscopic images of U118MG cells labeled for the cell nucleus (DAPI),
the mitochondria (Mitotracker Red), and TSPO (immunocytological labeling). The images are indicative
of morphological changes due to exposure to the TSPO ligand PK 11195, in association with intracellular
TSPO location. In general, as described in the text, the main points are that TSPO does not appear in
the cell nuclei, but are always co-localized with mitochondria. The arrow-heads indicate labeling of
mitochondria and TSPO evenly distributed throughout the cytoplasm in the vehicle row. In the 45 min
row, the arrows point at mitochondria with co-localized TSPO that are present relatively close to the
cell nuclei. A more detailed description of the figure follows here: The rows present exposure times to
PK 11195 (25 µM), from top to bottom: vehicle (i.e., no exposure), 30, 45 min, 1, and 24 h. In each row
from column to column the same cells are shown. Phase contrast micrographs are presented in the first
column. The second column shows cell nuclei (stained blue with the aid of DAPI) within the phase
contrast images. The third column shows TSPO immune labeling (Alexa fluorR 488, i.e., green) together
with the DAPI stained nuclei. Most importantly, the images in the third column show that TSPO
labeling is not within the cell nuclei, but in other intracellular areas and cell organelles. In particular,
there is no double-labeling of TSPO and DAPI signal. The fourth column shows mitochondrial labeling
in the cells outlined by phase contrast. Here it becomes clear that the TSPO labeling in the third column
covers intracellular areas occupied by mitochondria. The fifth column shows the results of all signals
for the cells in question combined. This presents merged double labeling for mitochon ria and TSPO
(white to yellow), while phase contrast and nuclear stain i applied for orientation. The DAPI stained
nuclei appear purple here due to interfer nce. As a control for this, omission of TSPO labeling i.e.,
by omitting the prim ry a ti-TSPO anti-body, results in the same nuclear stain (purple) when applying
the same microscopic conditions (not s own). As a general remark, omission of TSPO ntibody
co pletely preve ted the immunocytoche ical labeling for TSPO (not shown). T scale b r of 20 µm
in the lower left corner of the figure is for all the micrographs in this plate.
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Figure 7. Phase contrast microscopic images of U118MG cells labeled for the intracellular location of 
TSPO. In the left hand images, cells are only viewed for labeling of the cell nucleus (DAPI) and of 
TSPO (immunocytological labeling). In the right hand images, cells are viewed for labeling of the cell 
nucleus (DAPI), TSPO (immunocytological labeling), and the mitochondria (Mitotracker Red), within 
the cells outlined by phase contrast. While TSPO labeling can appear in the same area of view as the 
cell nucleus, double labeling of TSPO and nucleus does not occur (left hand images). In the right hand 
images it can be seen that the TSPO labeling overlaying the nucleus double labels with mitochondria, 
resulting in a yellow-whitish stain. The main points are that TSPO does not appear in the cell nuclei, 
but are always co-localized with mitochondria. In the vehicle exposed cells (top two images), labeling 
of mitochondria and TSPO is evenly distributed throughout the cytoplasm, almost completely filling 
out the cell body. In the cells exposed for 1 h to PK 11195, labeling of mitochondria and TSPO is 
condensed toward the cell nucleus, with TSPO—mitochondria double labeling appearing relatively 
close to the nucleus. Toward the periphery of the cell body a relative broad area is devoid of 
mitochondrial as well as TSPO labeling. The scale bar in the lower left micrograph of the figure is of 
20 µm for all the micrographs in the plate. 
We think is noteworthy to mention that we encountered a potentially interesting additional 
observation. At every time point of PK 11195 exposure, see for example the column of Figure 6 named 
“Nucleus, TSPO”, dense labeling of TSPO in relative proximity to the nucleus can be recognized in 
at least several of the PK 11195 treated cells (where this is most clear it is marked with white arrows). 
Such dense TSPO labeling can even become visible as “caps” adjacent to the cell nuclei. This is not 
apparent at all in cells not treated with PK 11195. The even spread of mitochondria labeled with TSPO 
throughout the cell body of vehicle control cells is indicated with white arrow heads in the top row 
of Figure 6. Examples of these phenomena are given as expanded images in Figure 7. For Figure 7 we 
chose the time points of 0 min and 1 h (i.e., with and without PK 11195 exposure), with the 
representations of: (1) labeling for TSPO, mitochondria, cell nuclei, and phase contrast for the cell 
outline to achieve a relatively complete overview of TSPO distribution inside the cell body; (2) 
labeling for TSPO and cell nuclei indicating the lack of TSPO labeling inside the cell nuclei, in 
unexposed as well as PK 11195 exposed cells. Thus, after PK 11195 exposure, TSPO labeling, as well 
as mitochondrial labeling, appears relatively condensed toward the nucleus, leaving more peripheral 
cellular regions free from this labeling , while in unexposed cells such labeling appears evenly spread 
Figure 7. Phase contrast microscopic images of U118MG cells labeled for the intracellular location
of TSPO. In the left hand images, cells are only viewed for labeling of the cell nucleus (DAPI) and
of TSPO (immunocytological labeling). In the right hand images, cells are viewed for labeling of the
cell nucleus (DAPI), TSPO (immunocytological labeling), and the mitochondria (Mitotracker Red),
within the cells outlined by phase contrast. While TSPO labeling can appear in the same area of view
as the cell nucleus, double labeling of TSPO and nucleus does not occur (left hand images). In the
right hand images it can be seen that the TSPO labeling overlaying the nucleus double labels with
mitochondria, resulting in a yellow-whitish stain. The main points are that TSPO does not appear in
the cell nuclei, but are always co-localized with mitochondria. In the vehicle exposed cells (top two
images), labeling of mitochondria an TSPO is evenly distributed throughout the cytoplasm, almost
compl tely filling out t ll body. In the cells exposed for 1 h to PK 11195, labeli g of mitochondria
and TSPO is condensed toward the cell nucleus, with TSPO—mitochondria double labeling appearing
relatively close to the nucleus. Toward the periphery of the cell body a relative broad area is e i
fi
i t l t .
We think is noteworthy to mention that we encountered a potentially interesting additional
observation. At every time point of PK 11195 exposure, see for example the column of Figure 6 named
“Nucleus, TSPO”, dense labeling of TSPO in relative proximity to the nucleus can be recognized in at
least several of the PK 11195 treated cells (where this is most clear it is marked with white arrows).
Such dense TSPO labeling can even become visible as “caps” adjacent to the cell nuclei. This is not
apparent at all in cells not treated with PK 11195. The even spread of mitochondria labeled with TSPO
throughout the cell body of vehicle control cells is indicated with white arrow heads in the top row
of Figure 6. Examples of these phenomena are given as expanded images in Figure 7. For Figure 7
we chose the time points of 0 min and 1 h (i.e., with and without PK 11195 exposure), with the
representations of: (1) labeling for TSPO, mitochondria, cell nuclei, and phase contrast for the cell
outline to achieve a relatively complete overview of TSPO distribution inside the cell body; (2) labeling
for TSPO and cell nuclei indicating the lack of TSPO labeling inside the cell nuclei, in unexposed as
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well as PK 11195 exposed cells. Thus, after PK 11195 exposure, TSPO labeling, as well as mitochondrial
labeling, appears relatively condensed toward the nucleus, leaving more peripheral cellular regions
free from this labeling , while in unexposed cells such labeling appears evenly spread over the cytosol.
Note, TSPO labeling only double-labels with mitotracker red (labeling for mitochondria), never with
DAPI (labeling for cell nuclei), even when TSPO labeling is in the same area of view as the cell nucleus.
Figure 6 provides a more differentiated overview, including changes in the morphology of cells during
the exposures to PK 11195. See a more detailed description of Figure 6 further below.
The scheme of Figure 8 presents some core observations of cell morphology presented in Figures 6
and 7. In particular, in vehicle control (0 h) TSPO labeling appears to be evenly spread throughout the
cytoplasm together with the mitochondria (top of Figure 8). As illustrated in the diagram of Figure 8,
commonly, in cells exposed to PK 11195, mitochondria with dense TSPO labeling can be seen relatively
close to the cell nuclei (from halfway down Figure 8 to the bottom of Figure 8). Also the basic time
dependent cell body shapes (round and polygonal) are diagrammatized in Figure 8. At the top of the
diagram of Figure 8, the cells (not exposed to PK 11195) are polygonal. One step lower in the diagram
of Figure 8, rounded cells are presented (i.e., cells exposed to PK 11195 for 15 and 30 min). From the
time point of 45 min of exposure to PK 11195, the U118MG cells start to disperse from the clusters and
revert to their typical polygonal and elongated shapes (bottom of the diagram of Figure 8).
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Figure 8. Scheme of observations presented in Figures 6 and 7. In vehicle control cells (i.e., 0 h of PK
11195 exposure) mitochondria with TSPO (yell ) re s read throughout the cytosol (grey). Shortly
after PK 11195 exposure the cell bodies contract, e roundish, and mitochondria with TSPO
appe r to become ore condensed toward the c l l i (blue). After 24 h of PK 11195 exposure the
cell bodies regain their original polygonal shapes. etheless, after these 24 h, mit chondria with
TSPO still remain congregated in areas relatively close to the cell nucleus. Mitochondria not displaying
TSPO signal are indicated with (red).
These observations are given here in more detail as a guide through the presentation of Figure 6.
Going down row by row with the sequential time responses to PK 11195 exposure in Figure 6, it can be
seen in the top row, or row 1 (named vehicle i.e., zero time exposure to PK 11195), that TSPO labeling
is relatively evenly spre d over the intracellular areas covered by mitochondria, withou distinct areas
of enhanced signal. This, for exampl , is indicat d by arrow heads at the inters ctions of ow 1 with
columns 3 and 5. The cells themselves are polygonal in shape and evenly distributed over the coverslip,
i.e., without clustering. In row 2 (30 min exposure to PK 11195) the cells have congregated to form
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clusters and frequently present roundish shapes, while the mitochondria with their TSPO appear to be
condensed toward the cell nucleus (presented at the intersections with columns 3 and 5). The same
is true for 15 min of PK 11195 exposure (not shown). In row 3 (45 min exposure to TSPO), the cells
appear to revert to their original morphology again (as in row 1). Nonetheless, mitochondria double
labeled with TSPO remain visible relatively close to the cell nuclei. This phenomenon is indicated by
arrows in the images of columns 3 and 5 intersecting with row 3. Note well that this phenomenon of
distinct TSPO signal present in mitochondria relatively close to the nuclei is observed at all time points
of PK 11195 exposure, i.e., in Figure 6 in all rows from row 2 to row 5, but not in row 1 (which is vehicle
control). In rows 4 and 5 (respectively 1 and 24 h of PK 11195 exposure), the cells continue to revert to
their original morphology and at 24 h have become indistinguishable from vehicle exposed U118MG
cells (row 1). The same is true for 3 h of PK 11195 exposure (not shown). The basic observations
are schematized in a relatively simple manner in Figure 8, presenting that TSPO only occurs in the
mitochondria in this paradigm, never in the cell nucleus.
The phenomena presented in Figures 6–8, were observed in two separate experiments, where
each condition was provided in 3 wells, and where at least 10 cells, or 10 clusters of cells from each well
were photographed. At present we cannot say what would be the cause, mechanism, or functional
significance for the observed enhanced TSPO signal in the relative proximity of the cell nucleus in PK
11195 exposed cells.
2.4. Actual Phenotypic Effects of PK 11195 Exposure That Were Predicted by Pathway Analysis
Several functional effects implicated by the changes in gene expression described above
could indeed be discerned by simple microscopic observations in our present study (Figures 6–8).
For example, functional effects predicted by the changes in gene expression at 15 min included
accumulation of cells, cell viability, and cell development (Table 3). Microscopically, accumulation of
cells after PK 11195 exposures was very conspicuous (Figure 6). This was particularly true at 15 min
and 30 min, and could still be discerned at 45 min (Figure 6). Note: accumulation of cells due to
PK 11195 exposure has not been described before. Thus, we could microscopically observe the cell
accumulation that was predicted by our gene expression assays. At 30 and 45 min, functional effects of
gene expression changes also implicated cell migration (Table 3). The congregation and segregation of
the cells under microscopic observations matched the cell migration effects implicated by the gene
expression analysis (Figure 6). Possibly the microtubule dynamics presented as an ‘Effect’ at 30 min
can be associated with changes in cell body shape observed microscopically (Figures 6 and 7). These
cell soma changes may be related to other functions, such as migration, adhesion, cell division, etc.,
which at present cannot be decided. After 1 h, cell migration no longer did appear to be a function
implicated by gene expression changes, and after 3 h such effect appeared to be reversed. Also under
the microscope, signs of cell migration could no longer be discerned after one hour of PK 11195
exposure. Regulator Effects analytic (IPA®) of Qiagen also suggested cell viability effects, as uncovered
at all time points. Indeed, previous experimental studies have presented PK 11195 at 25 µM to be a cell
protective agent (e.g., [5]), although at that time gene expression effects were not considered.
Another major effect of gene expression changes implied at different time points was cell
development and differentiation, even neuronal development and differentiation (from the time
point of 15 min till the time point of 3 h) (Table 3). The suggestion that exposure to PK 11195 can lead
to development and differentiation of neurons was a surprise, as U118MG cells are not considered
neuronal. We proceeded to test this potentiality in PC12 cells, which can be considered neuronal
progenitor cells. With previous studies we had shown that other, more advanced TSPO ligands
can induce neuronal differentiation from these neural progenitor cells, including enhanced tubulin
expression [46]. Indeed also in this study, PK 11195, without any additional treatment, just by itself,
could very clearly induce neuronal differentiation, including development of neurites and increased
expression of tubulin (Figure 9). The observed tubulin expression may be associated with microtubule
dynamics also observed with our gene expression assays.
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Figure 9. PK 11195 induced neuronal differentiation of rat PC12 cells. (A) Undifferentiated vehicle
control cells; (B) Neuronal differentiation due to PK 11195 (50 µM), including differentiating cells
(white asterisks), neurite outgrowth (white arrows), growth cones (white arrowheads), and varicosities
(black arrows); (C) Representative western blot showing elevated β-III-tubulin expression in rat PC12
cells after exposure times of 24, 48, 72, 96, and 144 h to PK 11195 (50 µM). β-actin is the loading control;
(D) Bar chart of Means ± SEM (n = 3) of the relative densities of the blot bands of β-III-Tubulin labeling
in C (arbitrary units as% of control. Control = vehicle treated cells. ** p < 0.01, *** p < 0.001. (In (A,B);
bars: 100 µm).
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As TSPO is well known to affect programmed cell death, we paid special attention to this issue.
PK 11195 exposure appeared to have a time dependent effect on gene expression related to programmed
cell death, as indicated by asterisks (*) next to the genes in question in Table 2: After 15 min, 11 out of
20 genes; after 30 min, 9 out of 14 genes; after 45 min, 8 out of 12 genes; after 60 min, 17 out of 25 genes;
after 3 h, 6 out of 14 genes; and after 24 h, 9 out of 29 genes. Thus, at all time points within 60 min
more than half of the genes changing expression are related to programmed cell death. After 3 h it is
less than half, and after 24 h less than one third (Table 2).
In general, apart from the functions discovered in the present study (e.g., accumulation of cells,
neuron differentiation), the functions revealed by Regulator Effects analytic; IPA® include numerous
well established TSPO functions (see Discussion and Introduction).
2.5. Effects of TSPO Ligands Other Than PK 11195 on Gene Expression
We chose PK 11195 to test potential induction of gene expression via TSPO, as PK 11195 is
a classical, well studied TSPO ligand, and the results can be in a relatively facile way incorporated
in the accumulated body of knowledge. Moreover, effects of 25 µm of PK 11195 are comparable to
TSPO knockdown (e.g., [32,39]). However, we also wanted to determine whether more advanced
TSPO ligands also present modulation of gene expression. To investigate this we applied different
concentrations of a recently developed TSPO ligand 2-Cl-MGV-1 [13,20,46]. For the study of potential
2-Cl-MGV-1 effects, we used the same microarray assay method as for PK 11195. We assumed that this
would give an indication of the specificity of the effects of PK 11195 as a TSPO ligand. We applied 1 h of
exposure as this was an effective time period as demonstrated for changes in gene expression following
PK 11195 application. We applied concentrations at the same height or higher than we applied for PK
11195 (i.e., 25, 50, and 100 µM), because the affinity of 2-Cl-MGV-1 is much lower than of PK 11195
(~240-fold) [46]. Furthermore, at 50 and 100 µM 2-Cl-MGV-1 does not show the confounding side
effects that PK 11195 shows at these concentrations [5,20]. In this paradigm 2-Cl-MGV-1 significantly
affected a small number of genes primarily related to gene expression regulation. Table 5 shows
the genes that are regulated by 2-Cl-MGV-1, namely: FOS, ZFP36, DUSP1, TUFT1, and ID2, and
This Table 5 shows that the concentrations of 50 and 100 µM 2-Cl-MGV-1 have robust effects on the
expression of these genes. A cut off of 1.5 as applied for PK 11195, showed changes due to application
of 50 and 100 µM of 2-Cl-MGV-1. Importantly, all the genes as seen in Table 5 are among the genes of
which their expression is most affected by PK 11195 (see Table 1). Thus, effects on these genes by the
TSPO ligands we applied in this paradigm appear to be quite specifically related to control of overall
gene expression.
Table 5. Dose dependent changes in gene expression of U118MG cells due to exposure 2-Cl-MGV-1.
50 µM 100 µM
Up-regulated genes ↑ Up-regulated genes ↑
FOS ↑ 2.5 FOS ↑ 3.46
ZFP36 ↑ 1.68 ZFP36 ↑ 1.72
DUSP1 ↑ 1.62 DUSP1 ↑ 1.71
Down-regulated genes ↓ Down-regulated genes ↓
TUFT1 ↓ 1.64 ID2 ↓ 1.68
2.6. General Observations
The TSPO ligand PK 11195, significantly and specifically, within 15 min induces changes in
gene expression. These gene expression changes are in accord with actual phenotypic and functional
changes. Microscopic observations imply mitochondrial TSPO in these phenomena.
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3. Discussion
To answer the question whether nuclear gene expression can be modulated via the mitochondrial
TSPO: (i) we first of all studied the effects of the classical TSPO ligand PK 11195 on gene expression in
general, in a time dependent fashion. (ii) We then applied pathway analysis to predict potential
functional implications. (iii) We also designed microscopic studies to study whether and how
TSPO location could be associated with modulation of gene expression i.e., to determine whether
(preferred) location of TSPO could change between mitochondria and nucleus. (iv) Microscopy was
also applied to study whether functions were actually modulated as predicted by our pathway analysis.
(v) Finally, comparisons with effects on gene expression by a more advanced TSPO ligand 2-Cl-MGV-1
were undertaken.
The early effect on gene expression (at 15 min of PK 11195 exposure) is an important indication
provided by the present study that TSPO may be an integral part of a pathway for regulation of nuclear
gene expression. PK 11195 is a specific TSPO ligand, known to affect numerous TSPO functions,
similar to the effects of TSPO knockdown by genetic manipulation [14,35,37,44]. The effects seen on
gene expression in the present study within this relatively short time of 15 min precede physiological
changes (in particular phenotypic changes) typically caused by TSPO ligands. In general, various
cellular functional changes in diverse cell cultures, including U118MG cells, typically are detected only
after 24 h of TSPO ligand treatment [5,14,35,37,52]. A detailed time response study by Costa et al. [40],
applying the covalent TSPO ligand irDE-MPIGA to GBM cells, showed that it takes more than 90 min
for irDE-MPIGA (25 nM) to irreversibly saturate all TSPO binding sites; 3 h after ligand application
∆Ψm collapse was observed; 6 h after ligand application externalization of phosphatidylserine was
observed and cell viability was reduced. After 24 h, de-novo TSPO synthesis was observed [40].
The present study shows that modulation of gene expression in U118MG cells due to PK 11195 occurs
hours before these previously reported physiological and phenotypic changes [5,14,35,37,40,52]. Thus,
the changes in gene expression appear to be the cause rather than the effect of such changes. Moreover,
Ingenuity pathway analysis (IPA®) also indicated that the first canonical pathway affected in our
paradigm, i.e., at 15 min, was restricted to regulation of overall gene expression. Furthermore, our
results showed that several key immediate early genes and transcription factor present a pronounced
peak in increased expression around 30 min of PK 11195 exposure. These key immediate early genes
and transcription factor are WNK1, SGK, FOS, DUSP1, and EGR1. As an additional test, also required
for follow up studies, we also have applied real time RT-PCR according to standard methods to
determine changes in expression of the immediate early genes FOS and DUSP1. With this RT-PCR
assay, we found that relative expression of FOS and DUSP1 in samples of PK 11195 treated cells
was increased in comparison to vehicle treated cells. In numbers, relative concentration of FOS
in cells treated for 30 min by PK 11195 was 7.5 compared to vehicle control, and for DUSP1 this
relative concentration was 3.5. This considerable increase in gene expression seen with real time
RT-PCR basically corroborates the microarray results of 30 min exposure to PK 11195. We selected FOS
and DUSP1 for this purpose, as their peak expression at 30 min with microarray is one of the main
indicators that the classical TSPO ligand PK 11195 can modulate nuclear gene expression, including
the canonical pathway for regulation of overall gene expression, as exemplified in Figures 1 and 2.
Also application of the TSPO ligand 2-Cl-MGV-1 for one hour to U118MG cells was indicative of effects
on gene expression, including immediate early genes and transcription factors: FOS, ZFP36, DUSP1,
TUFT1, and ID2. Thus, our experiments indicate that regulation of gene expression by different TSPO
ligands appears to be a reproducible phenomenon. Subsequently over the course of 24 h of PK 11195
exposure the effects on gene expression appeared to present a very dynamic process, i.e., apart from
the genes directly involved in regulation of gene expression, various genes affecting various functions
over this time period were affected. Finally, after 24 h, the gene expression in this glioblastoma cell
line of U118MG was regulated such that an anti-tumorigenic effect became most evident, including
promotion of programmed cell death. Furthermore, changes in gene expression observed after 3 h
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appeared to promote effects that counteract effects determined at shorter time periods, thus being
suggestive of a homeostatic effect.
Regarding the choice of the concentration of PK 11195 applied, with several previous studies
we found that PK 11195 at a concentration of 25 µM could optimally prevent programmed cell death
otherwise induced by various agents (ErPC3, glutamate, NO, CoCl2). To emphasize, these effects
25 µM of PK 11195 are similar to the effects of TSPO knockdown. For a review of these studies
see [10]. In the Kugler et al. study [5] it was determined that lower concentrations from 1 µM down
to 1 nM had no effect at all on programmed cell death induced by ErPC3. Just by itself, PK 11195
concentrations of 25 µM and lower (as low as 1 nM) had no effect at all i.e., appeared neutral. Higher
PK 11195 concentrations (in particular higher than 50 µM) presented increasing lethal effects on their
own, an effect that is well known [5,8]. Thus, this indicated to us that 25 µM of PK 11195 presented
modulation of TSPO function (reminiscent of the effect of TSPO knockdown, as mentioned) and
presented the optimal concentration to a priori avoid non-effects of lower concentrations and to avoid
confounding lethal effects of higher concentrations in this U118MG cell line. Furthermore, our first
study to assay the effects of PK 11195 on gene expression in general showed a time dependent
(from 24 to 48 h) effect of 25 µM of PK 11195 on gene expression [24], also reminiscent of the
effects of TSPO knockdown on gene expression [19]. With the present study we wanted to apply
shorter times of PK 11195 exposure to determine at which time points relevant changes in gene
expression occur. We also wanted to optimize the application conditions for our gene expression
studies. Therefore, we also took into consideration that full medium is known to be “activating”
regarding gene expression [53,54]. Thus, full medium might interfere with the gene expression
changes induced by PK 11195 or 2-Cl-MGV-1 and may complicate the issues at hand. This we strived
to avoid. In this context, serum free culturing medium is considered to be optimal for gene expression
studies as this renders cells quiescent [53,54]. Thus we applied serum free culturing medium. In short,
we applied a straightforward paradigm and simple methods to clarify restricted questions.
We firstly found that changes in gene expression occur relatively early after PK 11195 application,
i.e., already at 15 min. This is at least two hours before changes in physiological responses that are
typically associated with TSPO function [40]. Secondly, we found that within 15 min the classical
TSPO ligand PK 11195 induces considerable changes in gene expression associated with the canonical
pathway for modulation of gene expression in general. We also found that not only the classical
TSPO ligand PK 11195, but also the more advanced TSPO ligand 2-Cl-MGV-1 modulates expression of
immediate early genes and transcription factors. These basic approaches indicate that one of TSPO’s
functions is to modulate nuclear gene expression.
To further gain insights whether TSPO may modulate gene expression in a fairly direct way,
we applied microscopic determination of the intracellular location of TSPO. A priori, we expected that
after PK 11195 exposure TSPO may be found in the cell nucleus, as a result from various physiological
changes. This then would allow for fairly direct control of nuclear gene expression. However, with our
double labeling studies for TSPO, mitochondria, and cell nucleus, we always found TSPO to be located
in the cytosol, including the mitochondria, and never in the nucleus of U118MG cells, with and
without application of PK 11195, and at each time point of PK 11195 application, from 15 min till
24 h. The mitochondrial location of the TSPO suggested to us that the mitochondria-to nucleus
signaling pathway is the main venue for regulation of gene expression by TSPO. This well-known
mitochondria-to-nucleus communication pathway is conserved from yeast to humans and includes
mitochondrial release of Ca2+, ATP, and ROS generation [27–32]. Interestingly, at all time points of
PK 11195 exposure, we found that mitochondria intensely labeled for TSPO typically can be found
relatively close to the cell nuclei. This never occurred with cells not exposed to TSPO. At 45 min of
PK 11195 exposure, this was characterized by “caps” of mitochondrial populations expressing TSPO
in the relative vicinity of the cell nuclei. We would like to believe that the relative close presence to
the nucleus of mitochondria with TSPO may facilitate the regulation by TSPO of gene expression via
mitochondria-to-nucleus signaling. Of course, alternative explanations are possible, such as enhanced
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energy requirements in particular subcellular regions [26]. In addition, it appears that within 15 min
the application of PK 11195 causes the cells to contract to a round shape. This may contribute to
the change of location of mitochondria toward the vicinity of the cell nucleus (see Figure 7). Or, the
apparent location of the mitochondria is one of the contributing factors for cell shape change and
motility. Then, already at 45 min the cells appeared to return from the morphology of clustered
roundish cells back to polygonal cells evenly distributed over the culture plate. After 24 h, the cells
have returned to their original appearances. Nonetheless, throughout this whole period of PK 11195
exposure, mitochondria with their TSPO remain visible close to the cell nucleus. Thus, we postulate
that the morphological changes seen within 1 h of PK 11195 exposure, even starting already 15 min of
PK 11195 exposure may contribute to, or at least be associated with, TSPO’s ability to induce early
changes in gene expression. More studies, including high power light microscopy as well as electron
microscopy, are needed to elucidate the microscopic observations of the present study. We are fully
aware that a restricted number of other studies also show TSPO in other locations than mitochondria,
including cell nuclei [7,46,47].
The mitochondrial location of the TSPO suggested to us that the mitochondria-to-nucleus
signaling pathway is the main venue for regulation of gene expression by TSPO. As mentioned, this
well-known mitochondria-to-nucleus communication pathway is conserved from yeast to humans and
includes mitochondrial release of Ca2+, ATP, and ROS generation [27–32]. The mitochondria-to-nucleus
signaling pathway, as outlined in the Introduction, includes mitochondrial ROS generation and loss of
∆ψm, leading to changes in levels of ATP and NADH, and the release of Ca2+, resulting in the activation
of immediate early genes and transcription factors [29–32]. As also mentioned in the Introduction,
TSPO regulates mitochondrial ROS generation, ∆ψm transitions, ATP production, Ca2+ release, and
NADPH oxidase (NOX) activity [14–16,35–37,41–44]. In studies by others, effects on free radical
generation by TSPO ligands have been studied in cultured neural cells, including primary cultures of
rat brain astrocytes and neurons as well as cells of the murine BV-2 microglial cell line [55]. In these
studies, free radical production was measured at the time points of 2, 30, 60, and 120 min of treatment
with the TSPO ligands PK 11195, Ro5-4864, and PPIX (all at 10 nM). In astrocytes, all ligands showed
a significant increase in free radical production at 2 min. Thus, ROS generation induced by classical
TSPO ligands, synthetic and endogenous, apparently precedes changes in gene expression. As noted,
such ROS generation, may be an essential component of the mitochondria-to-nucleus signaling for
modulation of nuclear gene expression [26,56,57]. Finally, the present study shows that immediate
early genes which are characteristic of the mitochondrial-to-nucleus pathway (e.g., EGR1, FOS, and
MYC), are also induced by our application of PK 11195, the classical mitochondrial TSPO ligand. Thus
it appears that the well reported primary location of the TSPO in the mitochondria [7,9,11], which was
also observed in the present study, as well as TSPO’s well-known regulation of specific mitochondrial
functions, favors a mitochondria-to-nucleus signaling pathway for TSPO’s ability to regulate gene
expression. As strong quantitative changes in mitochondrial ROS generation, ∆ψm transitions, ATP
production, Ca2+ release, and NADPH oxidase (NOX) activity typically are inductive for programmed
cell death, we assume that moderate or small changes may rather be related to gene expression changes.
This is a subject wanting for research.
We also wanted to see whether the changes in gene expression match generally known TSPO
functions (as for example reviewed in [1,2,8,13]). To study this, we applied “Regulator Effects”
analytic provided by Ingenuity (info-ingenuity@qiagen.com). Indeed, the functions derived from the
gene expression changes matched with well-known TSPO functions. Briefly, “Regulator Effects”
analytic indicates that PK 11195 exposure time-dependently induces functional changes related
to: the cell cycle; programmed cell death; proliferation; migration; development, including cell
differentiation; cell viability; inflammatory and immune responses; and tumorigenesis. In the present
study, our microscopic observations also presented changes related to migration, development, and
differentiation, even correlating in a timely fashion with the changes in expression of the relevant
genes. Worldwide, careful TSPO research over the last 40 years has shown that PK 11195 and other
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TSPO ligands, as well as TSPO knockdown with genetic manipulation, modulate these same functions
as seen with the gene expression analysis in this study [1,2,8,10,11,19,36,40,42,44,55,58–60].
Importantly, the pathway analysis showed that the gene expression changes presented interactive
assemblies and super-assemblies. In short, in such assemblies, groups of genes provide several gene
products for singular functions. In simple terms, the predictions of effects on specific functions appear
to be robust. Moreover, the redundancies and degeneracies of pathways, forming the bases of the
assemblies and super-assemblies, reinforce the robustness of functional gene expression effects induced
by TSPO activity. It is well-known that redundancy and degeneracy in biological systems serve to
stabilize them [49–51].
The experiments of the present study also provide data that functional changes predicted by
observed changes in gene expression did actually occur. For example, the actual functional effects
observed in the present study appear to include: stimulation of gene expression and accumulation of
cells (at 15 min), activation of microtubule dynamics and cell motility (at 30 min), promotion of cell
migration (at 45 min), then cell motility and accumulation of cells is reversed (at 3 h). Only at 1 and
24 h of PK 11195 expression no gene expression related to the actually observed functional effects
was seen.
We were intrigued by the observed intracellular locality changes of TSPO labeling. It appears
that because of some until now unknown cause and purpose, mitochondria in the relative vicinity
of the cell nuclei enhance TSPO labeling in response to PK 11195 exposure. One alternative may be
that mitochondria with TSPO can move from more distant areas in the cytosol to areas neighboring
the cell nucleus, resulting in relative dense TSPO signal in such areas. This may potentially implicate
that mitochondria not expressing TSPO are not motile in this paradigm. Such a phenomenon is
not uncommon. For example in mature neurons, only one-third of axonal mitochondria are motile,
the remainder thus being stationary [33]. Stationary mitochondria are considered to serve as local
energy sources and buffer intracellular Ca2+ [33]. It is known that motility may serve to move
mitochondria to the required intracellular locations for various cellular functions, such as proliferation,
cell growth, cell cycle, differentiation, information transfer, apoptosis, etc. [31,56]. More studies are
needed to determine whether TSPO actually may modulate mitochondrial motility.
Finally, as alluded above, also TSPO ligands other than PK 11195 can regulate gene expression.
In the fifth approach of the present study this includes 2-Cl-MGV-1 which we found to modulate
immediate early gene expression. As the affinity of 2-Cl-MGV-1 by design is relatively low,
the concentrations of 2-Cl-MGV-1 given can be considered the equivalent of a 100 to 400 nM range of
PK 11195. This is closer to the dissociation constant of PK 11195 than the 25 µM concentration used for
PK 11195. Nota bene: in nature, a high affinity per se does not have to be advantageous. For example,
the affinity of CO for hemoglobin is 210 higher than that of O2. However, CO is lethal, O2 is life giving.
To further illustrate the potential general implications of our findings, other TSPO studies, applying
genetic manipulation and ligands other than PK 11195 to target various specific functions, also showed
modulations of gene expression [19,20,23,24,26,61–63].
In summary, our study indicates that the TSPO ligand PK 11195 can modulate gene expression
in U118MG cells within 15 min. This modulation involves regulation of expression of gene products
that are part of the canonical pathway for regulation of gene expression. This gene expression
appears to be related to cell viability and tumorigenicity of these U118MG cells. It is likely that such
modulation in gene expression occurs via mitochondria-to-nucleus signaling, probably via mechanisms
including ∆Ψm collapse, ROS generation, Ca2+ release, and ATP production (Figure 10). It is well
documented that these mechanisms are under the control of mitochondrial TSPO. The modulation of
gene expression by the TSPO elucidated in the present study (Figure 10) goes a long way in explaining
subsequent changes in cellular and organismal functions due to application of TSPO ligands. Thus,
we propose that TSPO’s mitochondrial functions include modulation of nuclear gene expression via
mitochondrial-nuclear signaling. This presents one way whereby TSPO can control several vital cell
functions, which has major implications for the whole organism in health and disease.
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implicated in these effects), followed by changes in gene expression for enzymes and other proteins. 
Eventual potential functional implications include cell proliferation, cell migration, cell 
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Figure 10. Regulation of gene expression by the TSPO ligand PK 11195. It is well known that the
classical TSPO ligand PK 11195 can modulate mitochondrial TSPO functions such as Ca2+ release, ATP
production, and ROS generation via modulation of mitochondrial proteins such as VDAC, ANT, and
complexV (a.k.a. ATP(synth)ase). Ca2+ release, ATP production, and ROS are part of the mitochondrial –
nuclear signaling pathway for regulation of nuclear gene expression. In this pathway, calcium sensitive
proteins such as calcineurin and calmodulinKIV contribute to induction of expression of immediate
early genes. The present study shows that PK 11195 exposure at first induces expression of immediate
early genes, as well as other transcription factors (calcineurin, and calmodulinKIV are implicated
in these effects), followed by changes in gene expression for enzymes and other proteins. Eventual
potential functional implications include cell proliferation, cell migration, cell differentiation, cell death,
inflammation, immune response, and tumorigenicity. While it is impossible to include all co-factors and
context conditions into this diagram, it should be appreciated that by making small and big variations
in the research paradigm, other final effects will become apparent regarding changes in function due to
changes in gene expression, for example as a consequence of application of other TSPO ligands, TSPO
knockdown, TSPO knockout, TSPO gene insertion, full medium, serum free edium, etc. The (*) and
the (**) next to the phenomena modulated by PK 11195 indicate results from our present study (*) and
from our previous studi s (**). # indicates data fr m st die by others. (We consider it worthwhile
for future studi s to pay attention to th calcium sensitive proteins in the cont xt of gene expression
regulation via TSPO activities).
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Caveats and Questions for Future Research
For most of its history, TSPO research has been challenged by oftentimes seemingly contradictory
results. In this section here we only want to present a minimal sketch of this problem. For this
short expose we provide a minimal number of references. For the interested reader, we refer to
the numerous reviews regarding TSPO research, which directly or indirectly approach this enigma
(not only referred to in this study, but also in other studies). It is well known that TSPO may contribute
to various functions, sometimes appearing without any commonality [64–69]. One may find that
for some researchers, gene regulation via TSPO or by TSPO ligands may be an undesired side
effect. For others, it may be a desired feature, for example to render cancer cells less malignant,
more differentiated, i.e., more like non-cancerous cells, or to induce regenerative responses to organ
and tissue damage. These antagonistic expectancies regarding properties of TSPO and its ligands
potentially may lead to widely divergent discrepancies in research approaches and interpretations
of results. Another confounding aspect does relate to the now well appreciated concept that
TSPO has homeostatic functions [20,23,26,38,62,63,70,71]. Assuming this to be true, many of the
seemingly contradictory results can be explained as upregulatory and downregulatory characteristics
of this potential homeostatic apparatus. An additional point, also redundancy and degeneracy
potentially can make interpretations regarding TSPO properties difficult, as mechanisms affected
by TSPO manipulations may be compensated for by other systems.It would be fascinating when
somebody finds a hard-core, well defined, characteristic and/or mechanism whereby TSPO can exert
its homeostatic functions.
A novel finding presented in Figure 8 should be discussed shortly. We observed two populations
of mitochondria, one clearly expressing TSPO and one population of mitochondria showing no
obvious presence of TSPO. To our knowledge, no quantitative studies have been performed regarding
differential presence or no of TSPO in mitochondria of individual cells. Thus, our observation (striking
to our minds) of mitochondria apparently with and without TSPO within one and the same cell
may be a first. From another perspective, but potentially also interesting in this context, it has been
observed that PK 11195 can regulate the conformation (folding or polymerization) of mitochondrial
TSPO [72]. One can speculate that this regulation of TSPO protein structure may be one manner
whereby immunological labeling of TSPO in mitochondria can be affected. At this point in time, one
can only say that more studies are needed to resolve this matter.
Figure 10 in the manuscript simply presents the factual observations of the present study
(indicated with * in Figure 10), as well as in previous studies by us (indicated with ** in Figure 10),
and by others (indicated with # in Figure 10). Figure 10 also presents the core sequential associations
between these observed facts. Table 6 below summarily lists these observations. Table 6 also points
out potential caveats and presents questions that can be addressed by future research. Regarding
each observation presented in the Table 6, it is obvious that a widely branched tree of assumptions,
postulations, questions, and research approaches will emerge in relation to each observation, not to
mention each potential caveat and questions associated with these factual observations. It is left to
the TSPO enthusiast, and the general interested reader, which approaches based on their experience,
expertise, and interests they feel should be pursued. It is obvious that with the very restricted number
of TSPO studies available till now that the final word defining TSPO and its related mechanisms
definitely has not been said. The authors here attempted to provide an aid for choice of questions
for future research. It has been well recognized that TSPO presents a target that can be utilized for
treatment of various diseases. In particular its characteristic as a receptor make it per definition a target
for the development of ligands designed cure such diseases [22,45,71,73].
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Table 6. Caveats and future questions regarding this and other TSPO research.
Observations Caveats or Questions Answer or Future Studies
PK 11195 applications affect
gene expression and the
related functions.
Is this context dependent? The application of PK 11195 can be furtherrefined (dose, time window, co-factors, etc.).
TSPO ligands other than PK 11195
affect gene expression and
related functions.
Is this context dependent?
If desired, the application of ligands other
than PK 11195 can be further refined
(dose, time window, co-factors, etc.).
TSPO knockdown affects gene
expression and related functions. Is this context dependent?
If desired, the application of TSPO
knockdown and knockout can be further
refined (transient, stable, time course of
effects, co-factors, etc.).
Interaction between PK 11195
and TSPO.
PK 11195 can interact with TSPO
to finally affect gene expression.
PK 11195 can also bind to
other receptors.
This can also occur via
other receptors.
Knockout all the other receptors binding to
PK 11195 (Difficult in practice).
TSPO can be knocked down to address
this question
(This has been done).
It can be checked whether other TSPO
ligands can affect gene expression
(This has been done).
Interactions between TSPO and
PK 11195 affect mitochondrial to
nuclear signaling, for example via
the initiating steps of ROS
regeneration, and Ca2+ and
ATP release.
Will different concentrations of
ATP and Ca2+ and levels of ROS
relate to different changes in
gene expression?
ATP and Ca2+ levels and ROS generation
can be measured after TSPO manipulations.
Gene expression can be measured.
Protein expression of calcium sensitive
proteins can be measured.
Mitochondrial to nuclear signaling
apparently induced by TSPO and
its ligands implicates various
calcium sensitive proteins.
Which calcium sensitive
proteins can be activated due to
TSPO modulations?
One can measure calcium binding proteins
after TSPO manipulations.
Immediate early genes and other
transcription factors are activated
as a consequence of TSPO
knockdown and TSPO
ligand applications.
TSPO ligands can act via other
receptors than TSPO.
TSPO knockdown can possibly be
compensated by various
cellular mechanisms.
One should not rely on one method to
induce effects of TSPO manipulation on
gene expression.
The time interval between measurements
after TSPO manipulation, such as
knockdown or knockout, or application of
TSPO ligands, or other agents affecting
TSPO activity should be as short as possible.
In this way, compensatory events
are precluded.
Immediate early genes induce
changes in expression of
other genes.
How is it ‘decided’ which genes
will be modulated?
One molecule such as PK 11195 by
itself cannot determine which
complex of genes will
change expression.
TSPO modulation has to be combined with
co-factors or different contexts. The
assumption is that these additional
variations, together with TSPO modulation
determine the patterns in changes of
gene expression.
For example switching from minimal to
maximal cell culture medium results in
major changes in numbers of gene
expression changes.
The final changes in gene
expression correlate with
functional changes.
Does this always occur?
Modulation of TSPO activity, modulation of
gene expression, and modulation of
function always have to be considered in
association with each other and subjected to
combined studies (an approach taken in the
present study).
Modulation of gene expression
typically has functional effects.
How important is control of TSPO
and its ligands of gene expression?
We think it is very important, at least in cell
culture and also in animal models we have
seen major phenotypic changes.
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4. Experimental Section
4.1. Materials
Cell culture materials were obtained from Biological Industries (Beit Ha’emek, Israel). PK 11195
was from PerkinElmer (Hopkinton, MA, USA). Stock solution of PK 11195 was 10−2 M in 100% ethanol,
kept at −20 ◦C. RNeasy Mini kit Qiagen and RNase–free DNase Set were from ELDAN (Petach
Tikva, Israel). Human HT-12v4.0 Expression BeadChip Kit-24 samples were obtained via Danyel
BIOTECH (Rehovot, Israel) from Illumina (San Diego, CA). DAPI Fluoromount-GR was from Southern
Biotech (Birmingham, AL, USA), MitoTrackerR Red CMXRos from Cell Signaling (Rehovot, Israel), anti
TSPO primary antibodies from Abcam (Cambridge, UK), and secondary antibody (AffiniPure, Alexa
fluorR 488-conjugated, Donkey Anti Rabbit IgG(H + L)) from Jackson ImmunoResearch (Philadelphia,
PA, USA).
Cell Culture
Cells of the human glioblastoma cell line U118MG were allowed to multiply under sterile
conditions, at 37 ◦C, under humidified air with 5% CO2, in full medium, i.e., MEM-EAGLE
supplemented with 10% fetal bovine serum (FBS), 2% glutamine, and 0.05% gentamycin, as described
previously [2]. For the gene expression studies and the preferred approach of serum deprived medium
was applied i.e., 0.5% FBS instead of 10% FBS, as this renders cells quiescent [53,54].
To study the effects of PK 11195 on neuronal differentiation, rat pheochromocytoma PC12 cells
of flat, polygonal and attached phenotype, were generously provided by Ilana Gozes of the Tel
Aviv University. This strain of PC12 cells has been studied extensively for differentiation effects of
various types of TSPO ligands [20,22]. The PC12 cells were cultured in DMEM supplemented with
8% fetal calf serum (FCS), 8% heat-inactivated horse serum (HS), 1% glutamine and 0.1% penicillin
(100,000 units/mL) + streptomycin (100 mg/mL) solution at 37 ◦C, 5% CO2, 90% relative humidity.
4.2. Exposure to PK 11195 and 2-Cl-MGV-1
U118MG cells (1.255 × 106) were seeded in Petri dishes (i.e., 28.5 × 103 cells/cm2) and allowed
to proliferate for 3 days in full medium. Experiments for gene expression assayed with microarray
typically consisted of three experimental groups and a vehicle control group (n = 3 for each group).
Serum deprived medium was applied for 24 h, in the experimental groups ending with the inclusion
of a choice from various TSPO ligand exposures. PK 11195 (25 µM final concentration) exposures were
for 15, 30, 45 min, 1, 3, or 24 h (the vehicle control group is without PK 11195 inclusion). To verify
whether other TSPO ligands could elicit gene expression effect, we also applied 25, 50, and 100 µM of
2-Cl-MGV-1 for one hour, according to the same paradigm as applied for PK 11195. 2-Cl-MGV-1 is a
recently developed TSPO ligand with glial protective and neuronal differentiation effects [13,20,22,45].
Exposure to PK 11195 and 2-Cl-MGV-1 implies serum deprived medium with 1% alcohol (vehicle),
PK 11195 (25 µM final concentration), or 2-Cl-MGV-1 (25, 50, and 100 µM) for the required time periods.
Previously we had found that 25 µM of PK 11195 is the optimal concentration for various types
of experiments with U118MG cells (e.g., [5,24,35,44]). The cells were collected by trypsinization,
washed by centrifugation in phosphate buffered saline (PBS) (400× g, 5 min), and lysed (RLT lysis
buffer provided with the RNeasy Mini Kit diluted with β-mercaptoethanol (1:100)), according to the
manufacturer’s instructions. Lysates were stored at −70 ◦C.
4.3. RNA Extraction
Lysates from 3.85 × 106 cells were taken for RNA extraction, according to the instructions of the
RNeasy® Mini Kit. Amount of obtained RNA was determined from a 1.5 µL sample by NanoDrop™
(Thermo, Rockland, DE, USA). For microarray assay, RNA was diluted to 50 ng/µL. RNA quality was
verified in 1 µL of each sample [19,24].
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4.4. Gene Expression Assay
100 ng of total RNA was amplified into biotinylated cRNA by in vitro transcription using
the TargetAmp Nano labeling kit for Illumina BeadChips (Epicentre, an Illumina Company).
The biotinylated cRNA was purified, fragmented, and hybridized to a HumanHT-12v 4.0 Expression
BeadChip, according to the instructions of the Direct Hybridization assay (Illumina). The hybridized
chip was stained with streptavidin-Cy3 (AmershamTM, GE Healthcare, Little Chalfont, UK) and
scanned with an Illumina HiScan. The scanned images were imported into GenomeStudio (Illumina)
for extraction and quality control. Then, the data were imported into JMP® Genomics software version
6.0 (SAS Institute, Cary, NC, USA), and statistical analysis was applied. The raw data are at the NCBI
data bank (File: GSE77998): http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77998. And
the second file (File: GSE85697) at: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85697.
4.5. Pathway Analysis
The raw data obtained with the microarray chip for gene expression assay were transformed
to log2 and filtered out for transcripts with expression at background level. Background signal was
provided by probes that contained scrambled DNA that does not correspond to any human DNA
sequence. Transcripts were also filtered out when they only showed differences of <5% between the
samples from the different time points (vehicle control = 0 h, and PK 11195 treatments for 15, 30,
45 min, 1, 3, and 24 h). Basic gene expression data analysis was performed using JMP® Genomics
version 6.0 (SAS, Cary, NC, USA). Principal component analysis and variance component analysis
were performed and followed by one-way analysis of variance (ANOVA). For selection of individual
genes with substantially changed expression, we applied a cut off of a minimal difference of 2-fold as
well as an adjusted p-value of ≤0.05 for multiple comparisons [74]. Furthermore, Ingenuity Pathway
Analysis (IPA®) software of QIAGEN [75] was applied. In particular, the “Regulator Effects” analytic
(IPA®) was applied to obtain insights in the known downstream “Effects” (functional, phenotypic,
disease related) related to genes with significant changes in expression (“Data Set”). Thus, the Data
Set comprises genes with changed expression in our study. This software also shows the upstream
“Regulators” (genes, RNAs, or proteins) that are known to be able to affect the genes of the “Data Set”
in relation to their known functional, phenotypic, and disease related effects.
4.6. Real-Time RT-PCR
U118MG cells (1.255 × 106) were seeded in Petri dishes (i.e., 28.5 × 103 cells/cm2) for treatments,
and allowed to proliferate for 3 days in full medium, just as for the microarray assay described
above. Then, as described above, serum deprived medium was applied for 24 h, prior to PK 11195
exposures. We prepared for real-time reverse transcriptase (RT)-PCR according to procedures described
previously [19,24]. Two biological duplicates were applied, each sample averaged from technical
duplicates. Amount of obtained RNA was determined from a 1.5 µL sample by NanoDrop™ (Thermo,
Rockland, DE, USA), as described above. RNA (1 µg) was reverse transcribed using the VersoTM
cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA). The resulting cDNA was used as a
template for TaqMan qPCR, using DUSP, FOS, and B2M specific primers and probes (Primer Design),
and ABsoluteTM Blue qPCR ROX Mix (Thermo Fisher Scientific, Waltham, MA, USA). B2M was used
as a normalizing gene. qPCR results were analyzed using Rotor-Gene Q 2.3.1.49 (QIAGEN) software.
4.7. Microscopic Studies
For triple labeling studies, cells were seeded in 6 well plates (each well holding a square
microscopic cover glass) at the exact same cell density and growing conditions as applied for mRNA
extraction i.e., 133 × 103 cells per well. Stock solution of PK 11195 was diluted (to 25 × 10−4 M) in
100% ethanol. MitoTrackerR Red was dissolved in 100% DMSO (1 µM). For experiments, MitoTrackerR
Red solution was diluted to a concentration of 100 nM in serum deprived medium (DMSO final
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concentration 0.01%). The treatments were 25 µM final concentration of PK 11195. Final concentration
of the vehicle was 1% of ethanol.
The time periods of PK 11195 exposure for the microscopic studies were 0, 15, 30, and 45 min,
and at 1, 3, and 24 h, ending together with the application of serum deprived medium for 24 h as
described above. At the last hour of this 24 h period, MitoTrackerR Red of 100 nM was applied. Then
the cells were fixated with 500 µL of 4% paraformaldehyde per well (2 × 20 min), and washed by
PBS (2 × 5 min), followed by 0.5% Triton in PBS-500 µL per well for 10 min. Then blocking solution
(5% bovine serum albumin (BSA) in PBS with 0.1% Triton) was applied for 1 h, followed by primary
antibody against TSPO, at a final concentration of 1:100 in blocking solution TSPO (500 µL for each
well), overnight at 4 ◦C. In one set, the primary antibody against TSPO was omitted. Next day, the
cover glasses with the cells in the wells were washed with PBS (with 0.1% Triton, 2 × 5 min), and
then the secondary antibody in blocking solution (1:100) for TSPO labeling was applied for 1 h at
room temperature. Then the cover glasses with the cells were washed with PBS (2 × 5 min), and
DDW (2 × 5 min), and coverslipped onto microscopic slides with DAPI Fluoromount-GR and dried.
Then these cells prepared for nuclear staining with DAPI, mitochondrial labeling with MitoTrackerR,
and TSPO immunofluorescent labeling with Alexa fluorR 488, were observed with the aid of an Axio
Observer z1 inverted microscope (Zeiss, Oberkochen, Germany), applying ZEN (Zeiss) for capture
and image analysis.
For microscopic studies of neuronal differentiation induce by PK 11195, exposure for 48 h to
50 µM of PK 11195 was applied. Changes in cell morphology of differentiating PC12 cells include
neurite sprouting, which is the hallmark of neuronal differentiation [20,22]. We used a Zeiss Axio
observer inverted microscope, a Colibri led illumination light source, and a high resolution B/W
CCD camera (Zeiss HS). Cell images were captured with the aid of Zeiss Axiovision 4.8 software for
data acquisition.
4.8. Western Blot Analysis of Tubulin Expression in Relation to Neuronal Differentiation
Protein levels of cell pellets were measured according to Bradford [76] using bovine serum
albumin as a standard. From PC12 cells treated with PK 11195 as described above, collected
samples of with equal amounts of protein (20 µg protein/lane) were prepared in 1× sample buffer
[0.125 M 2-amino-2-(hydroxymethyl) propane-1,3-diol (Tris)-HCl, pH 6.8, glycerol (20% v/v), SDS
(sodium dodecyl sulfate) (0.1% w/v), 0.14 M β-mercaptoethanol, and bromophenol blue (0.005% w/v)].
The 12% SDS-polyacrylamide gels were run and analyzed as described previously [77]. To detect
immunoreactivity related to our proteins of choice, we applied the appropriate primary antibodies:
Monoclonal Anti-β-tubulin III (neuronal) Clone 2G10 from mouse (T8578, Sigma, Rehovot, Israel) at
0.5 µg/mL, as advised by the datasheet instructions. Monoclonal Anti-β-Actin antibody produced in
mouse (A5441, Sigma, Rehovot, Israel) diluted 1:5000 was applied as a loading reference. The primary
antibodies were labeled with IgG secondary antibody linked to horseradish peroxidase (anti-mouse
IgG diluted 1:5000 as required; GE Healthcare, Buckinghamshire, UK). Binding of antibodies to their
antigens was detected with the EZ-ECL-detection reagent. Labeling was captured on X-Omat blue
XB-1 Kodak scientific Imaging Film. Band intensity was quantified by using Quantity one 1D-analysis
software (Bio-Rad, Hercules, CA, USA).
5. Conclusions
• Our study indicates that the classical TSPO ligand PK 11195 can modulate gene expression in
U118MG cells.
• Robust and significant changes in gene expression can already be seen within 15 min and appear
to be associated with cell morphological changes within the same time frame.
• At least at 15 min of PK 11195 exposure, expression of several elements of the canonical pathway
for regulation of gene expression in U118MG cells is enhanced.
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• After 24 h of exposure to PK 11195, changes in gene expression appear to be related to cell viability
and tumorigenicity of these U118MG cells.
• This modulation in gene expression most likely occurs via mitochondria-to-nucleus signaling,
probably via mechanisms including ∆Ψm collapse, ROS generation, Ca2+ release, and ATP
production (Figure 9). It is well documented by previous studies that ∆Ψm collapse, ROS
generation, Ca2+ release, and ATP production are under the control of mitochondrial TSPO.
• Thus, TSPO does not just modulate local mitochondrial functions, it also modulates nuclear
gene expression.
• Phenotypic changes predicted by the changes in gene expression did actually occur, e.g., cell
migration, cell accumulation, cell differentiation, and others.
• The novel TSPO ligand 2-Cl-MGV-1 also specifically modulated gene expression of immediate
early genes.
• The modulation of gene expression by the TSPO elucidated in the present study goes a long way
in explaining subsequent changes in cellular and organismal functions due to application of TSPO
ligands (Figure 9).
• Thus, modulation of nuclear gene expression via the mitochondrial TSPO can induce several vital
cell functions, which has major implications for the whole organism in health and disease.
• We believe that our study provides more understanding in the overall biological function of TSPO.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/4/786/s1.
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